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CASE PRESENTATION
A 22-year-old woman was referred to the University Hospital St.
Radboud eight years ago because of general fatigue, arthralgias, myalgias,
facial rash, and a fever (38.1°C). Her general physician had prescribed
salicylates and later nonsteroidal anti-inflammatory drugs, which partially
relieved the symptoms. Several years before, systemic lupus eiythematosus(SLE) had been diagnosed in one of her sisters who had had similar
complaints.
Physical examination of this healthy-looking, white female revealed a
typical butterfly rash on the face but no further skin abnormalities. Her
blood pressure was 140/70 mm Hg supine and standing, and the pulse rate
was 76 beats/mm and regular. She had no signs of anemia or edema. Oral
and genital ulcers were absent as was lymphadenopathy. None of the joints
showed signs of synovial swelling. Auscultation did not reveal a pleural or
a pericardial rub but did disclose a systolic murmur, grade JI/VI, at the left
fourth intercostal space and the apex. These findings suggested mitral
valve insufficiency, which was confirmed on echocardiography. Further
physical examination was unremarkable.
Laboratory examination revealed a sedimentation rate of 106 mm/br;
urea, 5.6 mmol/liter; creatinine, 91 mol/liter (1.0 mg/dl); and serum
albumin, 29 g/liter. A 24-hour urine collection contained 1.29 g of protein.
The urinary sediment contained 5—10 polymorphic erythrocytes/high-
powered field and numerous hyaline and red blood cell casts. The
hemoglobin was 6.1 mmol/liter; leukocytes, 3.0 >< 109/liter; and thrombo-
cytes, 222 X 109/liter. The LDH value was elevated to 372 U/liter. Liver
function tests all were normal. An antiglobulin test was strongly positive,
both with an anti-IgG and an anti-complement antiserum. Serologic
examination showed a strongly positive homogenous ANA, with a positive
Crithidia luciliae test indicating the presence of anti-dsDNA antibodies.
The Farr assay was strongly positive, with 5000 U/mI. The C3 and C4 levels
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were decreased to 559 and 99 mg/liter, respectively (normal values for C3:
750—1250 mg/liter; C4: 180—400 mg/liter). The immunoblot on nuclear
extracts was diffusely positive but did not disclose specific bands. Tests for
ANCA, rheumatoid factor, anti-cardiolipin, and cryoglobulins all were
negative. A chest radiograph and renal ultrasound examination did not
disclose any abnormalities. A percutaneous renal biopsy had to be
postponed because of a prolonged bleeding time due to the nonsteroidal
drugs. To relieve her arthralgias, prednisone (25 mg/day) was prescribed.
Two weeks later a renal biopsy was performed under ultrasound guidance.
The specimen contained 34 glomeruli, of which 40% showed capillary loop
necrosis with fibrin deposits. Cellular crescents were present in some
glomeruli. Endocapillary proliferation with influx of granulocytes and
mononuclear cells was seen in 80% of the glomeruli. The interstitium
contained a scarce, focal mononuclear cell infiltrate. Immunofluorescent
examination revealed coarse granular deposits of IgO (2±), 1gM (3+),
IgA (1+), Clq (4+), and C3 (4+) along the glomerular capillary walls and
to a lesser extent in the mesangium. Based on these findings, the biopsy
was classified as lupus nephritis WHO class IV.B with an activity index of
18 and a chronicity index of 1.
After discussing the therapeutic options, the patient selected treatment
with azathioprine and prednisone over cyclophosphamide and prednisone
because of the lower risk of infertility with the former regimen. Therefore,
the prednisone dose was raised to 60 mg/day, azathioprine was started at
a daily dose of 125 mg (2 mg/kg), and ranitidine was added prophylacti-
cally. During this treatment, her complaints disappeared completely, the
sedimentation rate fell from 106 to 30 mm/br, and the serum creatinine
decreased from 96 to 65 mol/liter (1.1—0.7 mg/dl). The urinary protein
excretion initially rose to 7.1 g/24 hr maximally, but thereafter decreased
gradually to 0.8 g/24 hr, although it never became negative. Concomi-
tantly, the serum albumin rose from 29 to 41 g/liter. Hematologic
parameters improved and became normal. The serologic immunologic
parameters also reflected the salutary effect of the treatment: the Farr titer
dropped to 140 U/mI (Fig. 1), and the C3 (but not the C4) level became
normal. The azathioprine dose was kept constant; the prednisone dose was
tapered every 4 weeks by 10mg/day until a dose of 30 mg/day was reached.
Thereafter, the dose was tapered every 4 weeks by 5 mg/day to a
maintenance dose of 10 mg/day, which was reached eight months after her
initial presentation. The course of the disease was unremarkable for five
months, until the urinary protein excretion again rose, from 2.0 to 7.4 g/24
hr, with a parallel decrease of her serum albumin from 44 to 33 g/liter. The
Farr assay, which had been negative, became positive again at 12 months
(see Fig. 1), and C3 decreased from 851 to 581 mg/liter. Clinically, she had
no signs of disease activity.
We discussed with the patient the option of starting intravenous
cyclophosphamide pulse therapy, but her fear of infertility prevented her
approval. The oral prednisone dose therefore was increased to 30 mg/day,
and she received three intravenous pulses of 1 g of methylprednisolone on
three consecutive days; the azathioprine dose remained unchanged. With
the new regimen, the proteinuria again fell to 2 g/24 hr, serum albumin
rose to 38 g/liter, and the Farr assay became negative again. The
prednisone dose was tapered as before. Within 12 months, the proteinuria
had again increased, reaching nephrotic-range values, with a gradual
decrease of the serum albumin level to 28 g/liter. Renal function deteri-
orated; the serum creatinine rose from 66 to 90 mol/liter (0.7—1.0 mg/dl).
The hemolytic anemia worsened, resulting in a hemoglobulin value of 5.8
mmol/liter. However, the white blood cell and platelet counts remained
normal. As depicted in Fig. 1, the Farr assay again became positive at 23
months. Treatment with cyclophosphamide still was not acceptable to the
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Fig. 1. Profile of the anti-dsDNA titers over time of the presented patient
as measured in the Farr assay (expressed as U/mi). Roman numerals
indicate Onset (I) or renal exacerbations (II, III, IV).
patient, so the oral prednisone dose was raised from 10 mg/day to 60
mg/day. Furosemide was prescribed for her edema. After this round of
intensification of treatment, the anti-dsDNA levels became negative, and
the C3 and C4 values returned to normal. The proteinuria responded only
partially (from 8 to 4 g124 hr), although the serum albumin levels rose to
34 g/liter. By 34 months after presentation (prednisone dose, 10 mg;
azathioprine dose, 125 mg), the serologic quiescence had ended; Farr
titers became positive again (100 U/mI). This development, together with
an increase in proteinuria and a decrease in serum albumin, led to the
decision to discontinue the azathioprine and to start monthly intravenous
pulses of cyclophosphamide. At months 37 and 38, she received I g of
cyclophosphamide together with hydration, ondansetron, and MESNA
(2-mercapto-ethane-sulfonate). Except for nausea after 48 hours, she
tolerated this treatment well. The next dose of cyclophosphamide had to
be postponed four weeks because of leukopenia. During that time, her
renal condition deteriorated; the serum creatinine rose to 161 mo1/liter
(1.8 mg/dl), the urinary protein excretion increased, and the serum
albumin decreased further to 22 g/liter. Her blood pressure rose to
170/110 mm Hg, for which she was given atenolol. Two weeks after the
third cyclophosphamide infusion, she was admitted to the hospital because
her renal function had deteriorated further (serum creatinine, 259 mol/
liter). Also, an increase in dsDNA titers indicated that serologically the
disease activity had increased (Fig. 1).
In an ultimate attempt to control the disease, the oral prednisone dose
was increased again to 60 mg/day, azathioprine therapy was reinstituted,
and plasmapheresis was started every other day for one week and
thereafter thrice weekly for two weeks. Blood pressure control was
improved by adding nifedipine and increasing the dose of furosemide. This
regimen led to a stabilization of renal function, with a serum creatinine of
about 300 tmo1/liter (3.4 mg/dl); a rapid decline of anti-dsDNA antibody
titers; and a normalization of serum albumin despite proteinuria of 8 g/24
hr. The prednisone dose was tapered as described. Beginning at 46
months, her renal function gradually deteriorated further, resulting in a
creatinine level of 620 mol/liter (7.2 mg/dl) (51 months post presenta-
tion) despite adequate blood pressure control, immunosuppressive main-
tenance therapy, and serologic disease quiescence. Standard measures
were taken (protein restriction, oral phosphate binders, 1c-hydroxy-
vitamin D1, erythropoietin substitution) to control the manifestations of
the progressive renal insufficiency. During extensive discussion, it was
decided not to increase the immunosuppression and to taper the azathio-
prine and prednisone, thus accepting eventual progression to end-stage
renal disease and opting for a renal transplant from a living-related donor.
Three months later, hemodialysis became necessary to control her
azotemia. In the meantime, preparations for the transplantation proce-
dure had been started. After blood group and HLA typing, her mother
offered a kidney. After a third-party blood transfusion and repeatedly
negative cross-matching thereafter, the renal transplant was performed
three months after hemodialysis had been started. The graft functioned
immediately, and the postoperative course was uneventful. Immunosup-
pression consisted of cyclosporine A and prednisone. The patient was
discharged on the 8th postoperative day in excellent condition; her serum
creatinine was 130 jimol/liter (1.5 mg/dl). Three months later, a percuta-
neous transplant biopsy was performed because of a rise of the serum
creatinine (to 168 j.mo1/liter; 1.8 mg/dl), which could not be attributed to
post-renal obstruction. This biopsy showed focally circumscribed areas of
mononuclear cell infiltrates and edema in the interstitium. Mononuclear
cells occasionally were present in the tubules. No glomerular abnormali-
ties were apparent. According to the Banif classification [1] these findings
were classified as "borderline interstitial rejection." There were no signs of
cyclosporine A nephrotoxicity. The patient was treated with intravenous
infusions of 1 g methyiprednisolone on three consecutive days. The serum
creatinine gradually decreased to 143 j.mol/liter (1.6 mg/dl). Over the past
four years, the serum creatinine has gradually risen again to its current
value of 165 mol/liter (1.8 mg/dI), but this increase paralleled her
increase in body weight from 46 kg at transplantation to 70 kg at present.
She currently is in excellent condition and has a full-time job. The urine
contains no protein. Her blood pressure is 130/84 mm Hg; she takes 50 mg
of atenolol daily. Her SLE has remained silent both clinically and
serologically since end-stage renal failure developed four years ago.
DISCUSSION
or flares of renal manifestations often are preceded by a rise in
titer of these anti-dsDNA antibodies 161 (Fig. 1), and anti-dsDNA
antibodies can be eluted from glomeruli in lupus nephritis [7].
Twenty-five years ago, this concept even led Koffler et al to
propose SLE, and more particularly lupus nephritis, as the
prototype of an immune-complex disease [81. Several crucial
pieces of evidence are lacking to support this central role for
DNA/anti-DNA complexes, however. Free DNA is not present in
the circulation [9, 10], the presence of DNA/anti-DNA complexes
in SLE is highly questionable [11], and glomerular localization is
rarely observed in experimental animals after intravenous injec-
tion of artificially prepared DNA/anti-DNA complexes [9]. There-
fore, alternative hypotheses have been developed.
The generation of monoclonal anti-DNA antibodies led to the
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DR. Jo H. M. BERDEN (Professor of Nephrology, Division of
Nephrology, University Hospital St. Radboud, Nijmegen, The Neth-
erlands): This patient illustrates the severe renal manifestations
complicating systemic lupus erythematosus. Like SLE itself, renal
manifestations of the disease are highly variable in their clinical
presentation, ranging from mild proteinuria to rapidly progressive
glomerulonephritis causing renal insufficiency within weeks [2].
This clinical variability is in keeping with the broad spectrum of
histologic abnormalities present in renal biopsy specimens from
these patients. The histologic findings in lupus nephritis are
categorized in six groups according to a recently modified World
Health Organization (WHO) classification (Table 1) [3]. A recent
Nephrology Forum specifically addressed the relation between
pathologic abnormalities and clinical symptoms [4]. Using the
case presented, I plan to focus on three other major aspects of
SLE: (1) new insights into the pathophysiology of lupus nephritis,
(2) treatment options in lupus nephritis, and (3) renal replace-
ment therapy in SLE.
A central feature of all renal biopsies from patients with lupus
nephritis is the presence on immunofluorescence examination of
immunoglobulin and complement deposits present either in the
mesangium (WHO class II) or in the mesangium and the capillary
loops (WHO class III, IV, or V) [3]. For many years, these
deposits were thought to be secondary to the deposition in the
glomerulus of DNA/anti-DNA immune complexes, because in
SLE anti-dsDNA antibodies are found in the circulation [5], onset
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Table 1. World Health Organization morphologic classification of lupus
nephritis (1995 revised versionf'
Class Description
I Normal glomeruli
A Nil (by all techniques)
B Normal by light microscopy, but deposits seen by electron or
immunofluorescenee microscopy
II Pure mesangial alterations (mesangiopathy)
A Mesangial widening and/or mild hypercellularity (+)
B Moderate hypercellularity (+ +)
III Focal segmental glomerulonephritis (associated with mild or
moderate mesangial alterations)
A Active necrotizing lesions
B Active and selerosing lesions
C Selerosing lesions
IV Diffuse glomerulonephritis (severe mesangial, endoeapillary, or
mesangiocapillary proliferation and/or extensive
subendothelial deposits. Mesangial deposits are present
invariably and subepithelial deposits often, and can be
numerous).
A Without segmental lesions
B With active neerotizing lesions
C With active and selerosing lesions
D With sclerosing lesions
V5 Diffuse membranous glomerulonephritis
A Pure membranous glomerulonephritis
B Associated with lesions of Category II (a or h)
VI Advanced sclerosing glomerulonephritis
a From Ref. 3.
In the previous version of this classification, membranous glomerulo-
nephritis accompanied by proliferative lesions in the capillary loops was
classified as V.C/V.D. In the modified version, these forms are categorized
in class [V.
discovery that some of these monoclonals could react with non-
DNA antigens [121, including intrinsic glomerular basement mem-
brane (GBM) constituents like heparan sulfate [13] and laminin
[14]. These observations suggested that anti-DNA antibodies
could directly bind to the GBM [9, 151. Subsequently, however, it
was demonstrated that histone/DNA (nucleosome) complexes
mediate the binding of these antibodies to cell surfaces [16], to
heparan sulfate [17], to laminin [18], and to endothelial and
mesangial cells [19]. The hypothesis then arose that the binding of
anti-DNA antibodies to the GBM in vivo was not direct, but
indirect, mediated by nucleosomes [20]. According to this con-
cept, the cationic histone part of the nucleosome is responsible for
the binding to heparan sulfate and to other anionic determinants
in the GBM. This concept was proven experimentally by renal
perfusion in vivo in rats of monoclonal anti-nuclear (anti-DNA
and anti-nucleosome) antibodies complexed to nucleosomes,
which indeed led to GBM binding, in contrast to lack of GBM
binding when non-complexed antibodies were utilized [21]. How-
ever, nucleosomes not only appeared to be important for the
evolution of tissue lesions and glomerulonephritis in particular,
but also for the induction of the autoimmune response in SLE.
Strong evidence indicates that the autoimmune response in SLE is
(auto)antigen driven and T-cell dependent [22—24]. This conclu-
sion is based on the following observations regarding anti-dsDNA
antibodies: (1) they are somatically mutated, (2) they show a
restricted rather than a random expression of VH and VL gene
products, (3) different individuals and different species share
common idiotypes, (4) they show a class switch to IgG and
predominantly to the T-cell-dependent IgG2a/2b isotypes, and (5)
Fig. 2. Composition of nucleosome. The central part of the nucleosome is
formed by the histone octamer, consisting of two pairs of the H2A-H2B
dimer and one H3-H4 tetramer. Around this octamer 145 bp of DNA are
wound in two superhelieal turns. Histone I-Il interacts with the octamer/
DNA complex and bridges, together with stretches of linker DNA,
adjacent nucleosomes. Note that the positively charged N-terminal regions
of the core histones are located at the outside of the nucleosome.
(Reproduced with permission from Scientific American. International
Edition, October 1992, from the article "Histones as regulators of genes"
by M. Grunstein, 40—47.)
it appears that CD4 T-helper cells are important for their
formation [24]. However, it is difficult to understand how DNA
can induce an autoimmune response, because the T-cell receptor
does not recognize oligonucleotides or naked DNA, but only
processed peptides presented in the groove of the MHC class-Il
molecule on antigen-presenting cells. Indeed, numerous reports
have shown that naked DNA itself is very poorly immunogenic
[reviewed in Ref. 24]. A major breakthrough was achieved when
it was found that the tolerance for dsDNA could be broken by
immunization of DNA complexed to DNA-binding proteins like
histones [reviewed in Ref. 25]. Thus the association with histones
appears to be critical for the formation of anti-dsDNA antibodies.
These observations provided the first indication that nucleosomes
arc important as triggering autoantigens in SLE [23, 26, 27].
New insights into the pathogenesis of lupus nephritis
Nucleosomes. Before addressing the relevance of nucleosomes
both for the induction and the effector phase in SLE, I want to
briefly review the structure of nucleosomes. The nucleosome, the
basic structure of chromatin, has an important function in the
compaction of DNA in the nucleus. It consists of pairs of the 4
core histones—H2A, H2B, H3, and H4—forming the histone-
octamer around which 145 bp of DNA are wound twice (Fig. 2).
Histone Hi anchors these DNA loops. Neighboring nucleosomes
are connected with histone-free linker DNA. This architecture is
responsible for the characteristic appearance of chromatin in
electron microscopy as "beads-on-a-string." Each of the 4 core
histones is a single polypeptide chain with a molecular weight
between Ii and 15 kD. Basic residues, which are clustered at the
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N-terminal regions of the core histones and therefore located at
the outside of the nucleosome, create regions with a strong
positive charge (Fig. 2). The positive charges on the cylindrical
surface of the histone octamer are partly involved in DNA
binding. But these regions of positive charges within the nucleo-
some also are important for binding to anionic moieties like
heparan sulfate in the GBM, as we will discuss later.
As I said, naked DNA is not present in the circulation [9], but
in 1990 Rumore and Steiriman showed that DNA does circulate in
the form of (oligo-) nucleosomes [281. The presence of DNA in
this particular form suggests that apoptosis is the source for the
generation of these nucleosomes. Apoptosis, a process of pro-
grammed cell death, leads to a non-phlogistic removal of "un-
wanted" cells. In contrast to accidental cell death by necrosis,
apoptosis can yield nucleosomes, because it starts with an inter-
nucleosomal cleavage of chromatin [291. This nucleosomal mate-
rial together with spliceosomes (snRNP/Sm) is clustered in the
so-called "apoptotic bodies," which appear at the surface of the
cell during apoptosis. Normally, apoptotic cells are phagocytosed
rapidly both by macrophages and by neighboring parenchymal
cells. This phagocytosis efficiently prevents the release of phlogis-
tic cell constituents into the micro-environment [30]. If apoptosis
or phagocytosis is disturbed, however, or if apoptosis occurs in the
circulation, nucleosomes can be released systemically. Under
in-vitro conditions in which effective phagocytosis is absent, the
amount of nucleosomes released strongly correlates with the
degree of apoptosis [31]. Apoptosis of lymphocytes can be in-
duced by several mechanisms, including T-cell receptor!CD3
activation or binding of the Fas receptor to its ligand [321. This
Fas receptor, belonging to the TNF receptor superfamily, is not
expressed in the spontaneous lupus model, the MRL/lpr mouse
[33]. This observation for the first time linked disturbed apoptosis
to SLE. Studies later reported that the defective expression of the
Fas ligand in the gld mouse had the same consequences, namely,
lymphoproliferation and systemic autoimmunity [34, 35]. Correc-
tion of the defective expression in both models by transgenic
techniques prevented the development of autoimmunity [36].
Overexpression of bcl-2, a physiologic inhibitor of apoptosis, also
leads to autoimmune features. It reduces the elimination of
autoreactive B-cells [371, induces the formation of anti-nucleo-
some antibodies, and leads to the development of immune-
complex glomerulonephritis [38]. In human SLE, the expression
of the Fas system is normal, but the increased concentrations of
soluble Fas (which inhibits apoptosis) reported by some [39] but
not all [40, 41] investigators, the increased expression of bcl-2 in
T-cells in lupus patients [42], and the increased rate of apoptosis
in vitro [31] point to abnormalities of apoptosis also.
These disturbances in apoptosis can have two major conse-
quences. First, they can lead to the persistence of autoreactive
T-cells [43], since apoptosis is the major mechanism for shaping
the T-cell repertoire in the thymus [32]. Second, they might lead
to quantitative and qualitative changes in the release of nucleo-
somes. This increased release of nuclcosomes might be further
augmented by defects in phagocytosis of apoptotic cells or by
impairment of C-reactive protein-mediated clearance of nucleo-
somes [44—46]. Both processes are disturbed in SLE. Further-
more, abnormalities in apoptosis can produce structural changes
in released nucleosomes, via oxygen-free-radical-induced protein
modification or fragmentation [47, 48]. This effect might create
novel epitopes within the nucleosome that induce activation of
Fig. 3. Profile of anti-dsDNA, anti.Clq, and nucleosome-specific anti-
bodies measured during the last renal exacerbation (episode IV in Fig. 1)
of the patient. Results are expressed as U/mI for the Farr assay and as
titers for the two other autoantibody specificities. For the latter, the titers
are the reciprocals of the dilutions that give an absorption of 1.0 at 450 nm
in the ELISA.
non-tolerant T-helper cells. The causative relationship between
apoptosis and autoantibody formation was demonstrated by the
observation that lupus-derived, nucleosome-specific autoantibod-
ies bind to nucleosomes either present in the apoptotic bodies [47]
or released from apoptotic cells [49]. In summary, it seems that in
genetically susceptible individuals, disturbances in apoptosis can
contribute to the development of SLE.
Nucleosomes are probably the major autoantigens that drive
the autoimmune response in SLE. First, Bell and coworkers
showed that nucleosomes can act as polyclonal B-cell activators
[50]. More important, since SLE is an antigen-driven disease,
nucleosomes, in contrast to dsDNA or histones, can stimulate
CD4 T-helper cells in murine lupus [51]. The same authors also
observed that these nucleosome-specific T-helper cells could
induce the production of anti-dsDNA and anti-histone antibodies
by syngeneic B-cells. Mamula recently suggested that this epitope
spreading is explained by the presentation to T-cells of previously
cryptic epitopes unmasked during processing by antigen-present-
ing cells [52]. Second, the formation of nucleosome-specific anti-
bodies, that is, antibodies that react exclusively with the nucleo-
some, but not with its constituents DNA or histones, is reported
with increasing frequency in SLE [reviewed in Ref. 53] and occurs
in as many as 80% of lupus patients [26, 54]. In our patient, we
retrospectively measured the anti-nucleosome titer in plasma
samples set aside during her last relapse (episode IV in Fig. 1). As
Figure 3 illustrates, an increase in nucleosome-specific antibodies
that mimicked the course of the anti-dsDNA titer accompanied
this last renal flare. Unfortunately no blood samples were avail-
able from the initial phase of her disease. Studies show that the
formation of these nucleosome-specific antibodies precedes the
formation of antibodies with other anti-nuclear specificity, for
example, anti-dsDNA and anti-histone [26, 55, 56]. At present not
enough data exist to relate nucleosome-specific antibodies to
certain SLE disease manifestations such as lupus nephritis. Until
now either a positive association [26, 49] or none at all [57] has
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been described. Third, a number of indications suggest that the
incidence of nucleosome-specific antibodies in SLE is higher than
thought because some anti-DNA antibodies are, in fact, nucleo-
some-specific antibodies. Anti-nucleosome antibodies complexed
to nucleosomal antigens can display anti-DNA reactivity in the
dsDNA-ELISA, but more important, also in the Farr assay [21],
which is regarded as the "gold standard" for the detection of
anti-DNA antibodies [58]. This DNA reactivity is caused by the
cationic histone within the nucleosome, complexed to the auto-
antibody. Removal of the bound nucleosomes abrogated this
DNA reactivity, but the nucleosome reactivity remained. This
phenomenon was first observed for monoclonal antibodies, but
evidence now suggests that it also applies to polyclonal antibodies
from patients with lupus. Exposure of Farr-positive blood samples
from SLE patients to high-salt conditions and DNAse reduced
Farr reactivity by 70%; reactivity towards other autoantigens
(nucleosomes/SS-A) or control antigens (EBV) remained unal-
tered [59]. Another indication that anti-DNA reactivity might be
due to nucleosome-specific antibodies comes from the observa-
tion that monoclonals with a high affinity for dsDNA bind even
better to nucleosomes than to dsDNA, as revealed by the mea-
surement of equilibrium affinity constants in a sensitive system
(60]. Taken together, these data indicate the importance of the
nucleosome as a dominant driving autoantigen in lupus, and
suggest that the loss of tolerance for nucleosomes is an initial key
event in this disease.
Besides their role as autoantigens, nucleosomes also participate
in the evolution of tissue lesions, especially glomerulonephritis.
The binding of antinuclear antibodies to nucleosomes (either in
the circulation or locally) can be a potential phlogistic threat for
the glomerulus. When we analyzed the "cross-reactivity" of anti-
DNA antibodies with heparan sulfate, we discovered that this
binding to heparan sulfate was not a direct binding but was
mediated by nucleosomes [17]. Because of the pivotal role of
heparan sulfate for the charge-dependent permeability of the
GBM [61], and the fact that neutralization of, or antibody binding
to, heparan sulfate leads to massive albuminuria [62], this auto-
antibody binding to heparan sulfate might be a critical pathophys-
iologic event. Thus the important question arose: Do histones and
DNA or, physiologically more relevant, nucleosomes mediate the
binding to heparan sulfate in the GBM in vivo? Indeed, we and
others have proved this to be the case both for histones/DNA [63,
64] and for nucleosomes [21], as analyzed in an in-vivo renal
perfusion system in the rat. Perfusion of non-complexed, purified
antinuclear autoantibodies did not lead to glomerular binding,
thereby refuting the previously suggested possibility of "direct"
binding to GBM constituents [9, 15, 65]. Removal of heparan
sulfate from the GBM (by prior perfusion with heparan sulfate-
degrading enzymes) considerably reduced GBM binding of nu-
cleosome-complexed autoantibodies but did not completely pre-
vent it [21]. Recent findings have indicated that collagen IV also
can act as a ligand for such nucleosome-complexed autoantibodies
[66, 67]. It is interesting that the presence of nucleosome-
complexed autoantibodies showed a high correlation with the
occurrence of lupus nephritis in both experimental lupus in mice
[68] and patients [69]. Because heparin has strong structural
similarities with heparan sulfate, we evaluated whether heparin
could inhibit the binding of nucleosome-complexed autoantibod-
ies to the GBM. In the in-vivo renal perfusion system, heparin
completely prevented this binding. Moreover, long-term adminis-
tration of heparin and non-coagulant heparin analogues in MRL/
lpr mice prevented immune-complex deposition in the glomerular
capillary loops, reduced the severity of the glomerulonephritis,
and prevented albuminuria [701.
What is the evidence that this nucleosome-mediated binding
occurs in lupus nephritis? (1) Analysis of GBM heparan sulfate
staining with immunofluorescence, using GBM-heparan sulfate-
specific monoclonal antibodies [62, 71], revealed a strong reduc-
tion of GBM-heparan sulfate staining both in human [72] and in
murine lupus nephritis [73]. This lack of staining was not due to a
reduction of the amount of heparan sulfate, but to masking of the
heparan sulfate by nucleosome-containing immune complexes
[73]. (2) Using nucleosome-specific monoclonal antibodies as a
probe, we recently identified for the first time nucleosomes in
glomerular immune deposits in 45% of the biopsy specimens from
patients with diffuse proliferative (WHO class IV) lupus nephritis
[74]. The presence of histones in 100% of these biopsies con-
firmed previous reports [75]. The difference between the fre-
quency of positive staining for nucleosomes and histones in the
deposits in these biopsies is in all likelihood due to the fact that
nucleosome-specific epitopes, in contrast to histone-specific
epitopes, are masked by autoantibodies bound to these epitopes
in vivo. Although the biopsy specimen of the patient presented
today could not be evaluated, a representative example from
another patient with WHO class IV lupus nephritis shows the
presence of nucleosomes and histones (Fig. 4). (3) Nucleosome-
specific antibodies can be eluted from glomeruli [56, 76]. In
summary, it appears that nucleosomes contribute importantly to
the development of lupus nephritis by targeting antinuclear
antibodies to the GBM.
Anti-Clq autoantibodies. In recent years it was found that
anti-Clq autoantibodies were associated with lupus nephritis. In
the 1970s, much attention was given to the measurement of
circulating immune complexes in various diseases [771. Although
widely employed in those years, these measurements have not
become a clinically useful tool for the diagnosis and management
of patients with autoimmune diseases. One of the methods used to
measure immune complexes was based on the interaction of these
complexes with the complement component Clq. But not only
high-molecular-weight material (immune complexes) interact
with Clq, but also low-molecular-weight 7S material [78]. This
"low-molecular-weight" 7S material was identified as antibodies
reacting via their antigen-binding site, and not via their Fc part,
with the collagen-like region of Clq. Although these antibodies
have been found predominantly in patients with SLE [79], the
presence of IgG anti-Clq is not restricted to patients with SLE; it
is also found in patients with mixed connective tissue disease,
ankylosing spondylitis, polyarteritis nodosa, mixed cryoglobuline-
mia, membranoproliferative glomerulonephritis, anti-GBM ne-
phritis [80], and in older healthy controls [81].
In a retrospective analysis of SLE patients, Siegert et al found
correlations between the titers of anti-Clq antibodies and the
occurrence of nephritis, hypocomplementemia, and titers of anti-
dsDNA antibodies [82]. This group confirmed the correlation with
nephritis in a prospective analysis; moreover, an increase in serum
anti-Clq antibodies was followed by the development of a prolif-
erative glomerulonephritis [83]. In the patient presented today,
we retrospectively measured the level of anti-Clq antibodies in
the blood samples obtained during the fourth renal flare (Fig. 1)
according to previously described methods [84]. As Figure 2
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of biopsy-proven proliferative glomerulonephritis (WHO class III
or IV), while increases in anti-dsDNA levels preceded all (renal
and non-renal) disease exacerbations in SLE. Increases in anti-
Clq coincided with increases in anti-dsDNA titers. The mean
time period between the occurrence of a significant increase in
anti-Clq or anti-dsDNA and the renal relapse was 2.3 months for
both autoantibody specificities. These observations led the au-
thors to suggest that serial measurements of anti-Clq levels might
be useful in predicting a renal relapse of proliferative lupus
nephritis [851. An intriguing question is whether these antibodies
have a pathogenic role in the development of the proliferative
glomerular lesions. In the proliferative forms of SLE glomerulo-
nephritis, Clq is abundantly present in the immune deposits. One
could envisage that this tissue-bound Clq can serve as a planted
antigen for anti-Clq binding [861, especially because these anti-
Clq antibodies do not bind to fluid-phase Clq but only to Clq in
the solid phase [84]. In this way, anti-Clq antibodies could amplify
an ongoing glomerular inflammation.
Treatment options in lupus nephritis
Fig. 4. Representative examples of immunofluorescence microscopy of a
renal biopsy of a patient with diffuse proliferative lupus glomerulonephri-
tis (WHO class IV). A Staining with a polyclonal rabbit anti-H3 1—21
antiserum (kindly provided by Dr. Sylviane Muller, CRNS Strassbourg,
France). The staining reveals abundant histone deposits in the walls of the
capillary loops (x 300). B Staining obtained with a mouse nucleosome-
specific monoclonal antibody LGIO—1 (generously provided by Dr. Marc
Monestier, Temple University, Philadelphia, Pennsylvania). In addition to
prominent anti-nuclear staining, nucleosomc deposits are seen segmen-
tally in the capillary loops (indicated by arrows) (x 200).
shows, we indeed noted a significant rise in the anti-Clq antibody
titer during her last renal exacerbation. Recently, a prospective
study investigated whether increases in anti-C1q antibody titers
could better predict renal manifestations in SLE than could rises
in anti-DNA titers [85]. This study was carried out in the same
patients in whom Kallenberg's group established that measure-
ments of anti-dsDNA titers can predict lupus disease flares [6],
Increases in anti-Clq levels were associated with the occurrence
There is no definitive cure for SLE and thus none for lupus
nephritis. Therefore, the major aim of treatment is to reduce the
symptoms and halt progression of the disease. Because many of
the drugs currently used have considerable side effects, the choice
of treatment should be based on balancing the benefits and risks.
Proper assessment of the pros and eons requires prospective
randomized trials showing the efficacy and side effects of the
various therapeutic options. This starting point, however, imme-
diately poses a problem: only a few such studies are available,
those mainly carried out at the U.S. National Institutes of Health
(NIH). Also needed is an appropriate measure of disease activity,
especially because the course of SLE is so unpredictable. Ideally,
this measure would monitor overall disease activity. Several
scoring systems have become available [87, 88], but few of these
have been used longitudinally. Therefore, most studies on the
treatment of lupus nephritis do not provide data on the overall
disease course and focus on "renal" end points [doubling of serum
creatinine or development of end-stage renal failure (ESRF)].
Various studies on the prevalence of ESRF in lupus make clear
that the great majority of patients who progress to ESRF have
either a WHO class-Ill or class-IV glomerulonephritis. We are
therefore justified, I believe, in reserving the more aggressive
treatment modalities for patients with these proliferative forms of
lupus nephritis. No controlled trials have evaluated treatment of
other forms of lupus nephritis (mesangial, class II or membra-
nous, class V), so treatment recommendations for the latter forms
are based on empiric grounds and open studies. In general,
treatment with corticosteroid monotherapy in mesangial lupus
nephritis (WHO class II) produces satisfactory results [2]. Some
authors even advocate not treating the renal lesions, but directing
therapy at the extrarenal manifestations [89, 90]. In any case, one
should be aware of the possibility that the lesion can progress to
a proliferative form [89]. This transformation generally is her-
alded by nephritic urinary sediment and an increase in protein-
uria.
We currently treat SLE patients who have a pure membranous
glomerulonephritis with a combination of corticosteroids and
azathioprine (AZA). However, Sloan et al recently found, in a
retrospective analysis, that SLE patients with a pure membranous
glomerulonephritis (WHO class V.AJV.B) who were treated with
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prednisone monotherapy had an excellent renal survival. In
contrast to this, patients with membranous lupus nephritis accom-
panied by proliferative lesions (the former WHO class V.C/V.D;
see Table 1) had a much worse prognosis, even though most of
these patients also had received cyclophosphamide (CPM) or
AZA [91]. This study clearly indicates that the course of mem-
branous glomerulonephritis formerly classified as WHO class
V.CIV.D differs from that of membranous glomerulonephritis
classified as WHO class V.AJV.B. If renal function is impaired or
deteriorates in a patient with pure membranous lupus glomeru-
lonephritis, one could consider treatment with oral CPM to
preserve renal function, as suggested for idiopathic membranous
glomerulonephritis [921. In contrast to this, monthly intravenous
CPM pulses did not preserve renal function in prospective
randomized studies in patients with idiopathic membranous gb-
merulonephritis [93, 94]. Unfortunately, no such controlled stud-
ies are available on membranous lupus nephritis, so we do not
know whether CPM should be used for the treatment of lupus
membranous glomerulonephritis. If CPM is prescribed, the expe-
rience in idiopathic membranous glomerulonephritis suggests that
continuous oral administration is preferable over monthly intra-
venous pulses. Because of the lack of data on long-term effects of
CPM treatment in lupus membranous glomerulonephritis, Appel
and Valeri suggested that if treatment with CPM is instituted, the
treatment should be evaluated after six months; if treatment is
unsuccessful, the drug should be discontinued [90]. The experi-
ence with cycbosporine A (CsA) in membranous lupus nephritis is
limited. Although CsA reduced proteinuria in all patients in one
study, in 4 of 10 patients proteinuria increased again after
cessation; more worrisome, glomerular lesions progressed in all 5
patients rebiopsied [95]. Furthermore, CsA induced hypertension
and nephrotoxicity in one-half of patients, was associated with
disease flares after drug cessation, and did not influence autoan-
tibody production [96]. Although obtained in a small number of
patients, these results suggest that CsA is not a reasonable
therapeutic option in SLE.
The occurrence of a pure interstitial nephritis in SLE is rare,
and the literature contains no therapeutic guidelines for it. We
can reasonably assume that this condition should be treated like
other forms of non-SLE acute interstitial nephritis. That is,
therapy could comprise oral prednisone monotherapy, in severe
cases preceded by a short course of intravenous methylpred-
nisolone [97, 98].
For advanced glomerulosclerosis in lupus (WHO class VI),
intensification of immunosuppression confers no benefits. Treat-
ment for this group of patients focuses on the extrarenal lupus
manifestations and on alleviating the consequences of chronic
renal insufficiency (protein restriction, antihypertensive treat-
ment, oral phosphate binders, vitamin D analogues, and erythro-
poietin substitution). With the good results that renal replace-
ment therapy offers patients with SLE, we should not expose
patients with irreversible renal lesions further to the risk of
immunosuppression (until the time of transplant).
Cameron analyzed the five-year patient survival of patients with
WHO class IV glomerulonephritis over the last 40 years and
noted a steep increase in the early 1970s, from about 25% in the
decade before to 76%—78% [99]. This improved outlook undoubt-
edly is due to the introduction of cytotoxic drugs (mainly AZA
and CPM) into the therapeutic armamentarium and to the
increased availability of dialysis to treat ESRF. A meta-analysis by
Felson and Anderson made it clear that the addition of cytotoxic
immunosuppressive drugs (AZA or CPM) to prednisone im-
proved renal survival in comparison to treatment with prednisone
alone [100]. The histologic analysis by Balow and colleagues
explained this beneficial effect [101]. In repeat biopsies of SLE
patients treated with prednisone monotherapy, the chronicity
index increased on average 1.4 points/year; in the AZA- or
CPM-treated patients, this index remained stable over time. The
same investigators were the first to report that a chronicity index
of more than 3 (on a total score of 12) strongly predicted ESRF
[102]. These observations raise the question: which of the two
cytotoxic drugs, AZA or CPM, is superior? Clinical trials from the
NIH showed that drug regimens containing either intravenous or
oral CPM were superior to prednisone alone in terms of prevent-
ing ESRF [103, 104]. But AZA, combined with low oral doses of
prednisone, did not significantly differ from CPM-containing
regimens or from prednisone monotherapy. Further, the NIH
studies showed that a regimen of monthly intravenous pulses of
CPM was comparable to continuously used oral CPM in terms of
efficacy, but was less toxic [103]. Although desperately needed, no
further controlled trials have compared CPM and AZA in terms
of efficacy and toxicity.
Cameron [99] tried to overcome this lack of information by
comparing both the renal and patient survival of patients with
diffuse proliferative lupus nephritis treated with either CPM [103]
or AZA [99, 103, 105—107] and found no differences in either
renal or patient survival. Cameron's comparison conforms with
the results of the NIH studies, which also found no differences
between CPM and AZA [103, 104]. The superiority of CPM over
AZA thus has not been proven. This conclusion is important in
view of the severity and higher frequency of side effects of CPM.
Treatment with CPM is associated with amenorrhea in 50% to
70% of patients after long-term oral use and in 30% after
intravenous administration of CPM pulses [108]. In patients given
intravenous pulses of CPM, the incidence of amenorrhea in-
creases with the number of pulses and the patient's age [108]. The
fear of this side effect caused the patient presented today to refuse
treatment with CPM on three occasions. Data on the effect of
CPM on spermatogenesis are curiously lacking. One report about
CPM therapy for nephrotic syndrome due to minimal-change
disease suggests a threshold of 12 to 17 g as the cumulative dose
above which oligospermia can occur [1091. These data contrast
sharply with the effects of AZA on gonadal function. Experience
gained from renal transplant patients indicates that AZA does not
affect reproductive ability both in men and women. Even preg-
nancies during which AZA is administered are relatively safe,
showing only a slight increase in congenital malformations [110].
In contrast, giving CPM during pregnancy is absolutely contrain-
dicated because of its strong teratogenic potential. Uro-epithelial
toxicity, ranging from hemorrhagic cystitis to invasive bladder
carcinoma, is also a unique side effect of CPM. This complication
occurs more frequently after oral than after intravenous admin-
istration of CPM and is related to the total cumulative dose [103,
1111. Treatment with long-term oral CPM is associated with the
development of hemorrhagic cystitis in 17% of lupus patients
[103] and in 43% of patients with Wegener's disease [112]. In this
latter group of patients, 2.8% developed bladder cancer, which
represented a 33-fold increase in the risk for this complication. An
increased frequency of other malignancies, mainly non-Hodgkin's
lymphoma (relative risk: 10.9) and skin cancers (relative risk: 5),
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is observed during treatment with AZA or CPM [113]. Although
we have no good data that compare the carcinogenic potential of
these drugs, we have more long-term experience with AZA.
In addition to oral prednisone, AZA, or CPM, another thera-
peutic modality frequently employed in the treatment of lupus
nephritis is intravenous pulses of high doses of methylpred-
nisolone (ivMP). These high dosages of steroids likely have a
more rapid and a stronger effect on the inflammatory and
autoimmune response than does oral prednisone [89]. A number
of uncontrolled studies [reviewed in Ref. 89] and one controlled
study [114] showed that ivMP in conjunction with low doses of
oral prednisone promptly improved renal function and autoim-
mune parameters in most patients, but the effect on proteinuria
took longer. These studies also suggested that the ivMP/low-dose
oral prednisone regimen had higher efficacy combined with lower
toxicity when compared to high oral doses of prednisone alone.
None of these studies, however, established the long-term effect of
ivMP on the preservation of renal function. The histologic fol-
lowup study by Balow et a! [101], which evaluated oral prednisone
treatment, raises the question whether treatment with steroids
alone can prevent the progression of chronic lesions. Indeed, a
prospective randomized study from the same group compared six
monthly ivMP pulses with intravenous pulses of CPM adminis-
tered for six months (6 pulses) or 30 months (14 pulses) and found
that treatment with ivMP was associated with a significantly
greater risk for deterioration of renal function and a higher
relapse rate than treatment with CPM pulses [1151. Thus ivMP
alone, without cytotoxic drugs, constitutes insufficient treatment.
What conclusions can we draw from these studies? First, it has
not been proven that AZA is less effective than CPM, but it is
certainly less toxic. Second, in the initial treatment of lupus
nephritis, ivMP is as good as high dosages of oral prednisone (1.0
mg/kg) but has fewer side effects. Therefore, a combination of
AZA (which prevents progression of chronic lesions) and an
induction treatment with ivMP (which rapidly induces regression
of the acute lesions) might be an ideal combination, combining
efficacy with less toxicity. A recent report from the Academic
Medical Center of the University of Amsterdam showed, unfor-
tunately in an uncontrolled study, that this combination therapy is
effective and associated with little toxicity [1161. Thirteen patients
with recent-onset (median duration, four months) diffuse prolif-
erative lupus nephritis (mean serum creatinine, 109 jkmol/liter
(1.2 mg/dl); GFR, 58 mi/mm) were treated with three courses of
I g ivMP given three times (2 and 4 weeks apart), 20 mg oral
prednisone, and 2 mg/kg AZA. This regimen improved renal
function in all patients (mean serum creatinine, 68 j.mol/liter (0.7
mgldl); GFR, 102 mi/mm at mean followup of 7 years), reduced
proteinuria (only four had 1.0—1,5 g/24 hr at last followup), and
improved serologic parameters. Side effects occurred in two
patients: re-entry tachycardia and septicemia. Although herpes
zoster developed in one patient, no other major bacterial, viral, or
opportunistic infections occurred. The promising results of this
uncontrolled study prompted the Dutch Working Party on SLE to
embark recently on a national, prospective randomized trial
comparing intravenous pulses of CPM (6 monthly pulses, and
quarterly pulses for the following 18 months) and high oral doses
of prednisone (1 mg/kg) with the combination therapy of ivMP,
prednisone, and AZA [as described in Ref. 117]. The results of
this study should provide more definitive conclusions regarding
the efficacy and side effects of CPM/prednisone versus AZAJ
prednisone treatment.
Finally, let me say a few words about the therapeutic potential
of plasmapheresis in lupus nephritis. Although two groups
claimed positive short-term effects in uncontrolled studies [118,
119], subsequent randomized trials failed to confirm their enthu-
siasm [120, 121]. A large-scale, prospective randomized trial
provided a definitive answer regarding the efficacy of plasma-
pheresis [122]. The addition of plasmapheresis to immunosup-
pressive therapy did not confer a significant benefit. Although the
results of a prospective German study employing sequential
plasmapheresis and intravenous CPM are not yet available [123],
it seems justifiable to conclude on the basis of current information
[124], that plasmapheresis is not a useful adjunct to immunosup-
pressive therapy in patients with lupus nephritis.
Intensification of immunosuppressive treatment is generally
indicated if a renal flare develops. The identification of such an
exacerbation usually is based on changes in clinical parameters,
such as an increase in hematuria or proteinuria, or a deterioration
of renal function. The observation that 89% of renal and non-
renal disease flares occur 10 weeks after a significant rise of the
anti-DNA titer [6] led Kallenberg's group to investigate whether
these relapses can be prevented by increasing the prednisone
dose, irrespective of clinical symptoms, if such a rise in anti-
dsDNA occurs [125]. Anti-dsDNA titers were measured monthly
with the Farr assay. If the anti-DNA titer rose more than 25%,
patients were randomly assigned to either continuation of their
current medication or to a 30 mg increase of their current
prednisone dose. The titer rose significantly in 46 of 156 patients;
24 were randomized for continuation of their existing medication,
and 22 patients were given an increased prednisone dose. The
relapse rate was higher in the group with unchanged medication
than in the prednisone group (20 versus 2, P < 0.001), but a
significant difference was noted (P < 0.001) only for minor
relapses and not for major relapses (P = 0.12). Renal relapses
occurred five times in the conventional treatment group and two
times in the prednisone group; this difference was not significant.
Furthermore, this approach did not lead to a difference in the
cumulative or mean daily dose of prednisone after randomization.
Therefore one has to conclude that this serologically guided
treatment protocol cannot prevent renal relapses. It remains to be
determined whether the use of a different serologic marker
(possibly nucleosome-specific antibodies or anti-Clq antibodies)
can yield more favorable results.
Renal replacement therapy in SLE
Progression to end-stage renal failure. The patient presented
today developed ESRF within four years. Nossent's recent review
of the literature indicates that this complication develops in
approximately 20% of the patients with lupus nephritis (Table 2)
[126]. These data suggest that the incidence of ESRF has been
relatively stable over the last three decades. In most studies, the
mean time between onset of lupus nephritis and ESRF is five
years [127, 128]. Nossent and colleagues in cooperation with the
Dutch Working Party on SLE studied 55 SLE patients who
developed ESRF [128]. These patients had at least one, and
sometimes more, renal flares after the onset of nephritis, as did
the patient presented here. The standardized SLE Disease Activ-
ity Index (SLEDAI) [129] applied at three-month intervals re-
vealed that in the period preceding ESRF, 15% of the scores were
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Time period
Number of
patients with
lupus nephritis
Number of
SLE patients
with ESRF Percentage
1950—1960
1961—1970
1971—1980
1981—1992
All periods
54
301
601
317
1273
26
40
145
58
269
48.1
13.3
24.1
18.3
21.1
a Recalculated from data reviewed in Ref. 126.
Factor Reference
Elevated initial serum creatinine (in most [91, 105, 133, 140—1441
studies  100 imol/liter, 1.1 mgldl)
Nephrotic-range proteinuria [105, 144, 145]
Low C3 [105, 143, 146]
Hematocrit  26% [143, 146]
Hypertension [143]
WHO class IV [102, 105, 133, 140, 147]
Activity index  12 [102, 140, 142, 1431
Chronicity index  3 [102, 105, 140, 142, 143]
No normalization of elevated serum [141]
creatinine at 48 weeks
Treatment with prednisone only [100, 104, 1481
Persistent disease activity [105, 1261
Male gender [128, 135, 140]
Black race [143, 146, 149, 1501
Age 24 years [105, 140]
Low socioeconomic status [149]
high ( 10) and 51% were moderately high. The regression line of
all SLEDAI scores over time prior to dialysis showed a slow but
significant rise. These observations indicate that, in general, this
group of patients had active disease before reaching ESRF.
Furthermore, in the period before reaching ESRF, disease quies-
cence is exceptionally rare in lupus patients progressing to renal
failure [126]. Therefore, as one would expect, persistent or
remittent disease activity is a major risk factor for ESRF.
The literature cites a number of other factors that increase the
risk for ESRF in patients with lupus nephritis (Table 3). Not all
these parameters have been confirmed in all studies, probably
because of differences in definitions used, composition of the
cohort studied, duration of the followup, and the number of
patients included. Many of these risk factors were present in
today's patient: hypertension, nephrotic-range proteinuria, low
C3, WHO class IV, activity index  12, remittent disease activity,
and age  24 years).
Dialysis. Hemodialysis initially was not offered to lupus nephri-
tis patients because of the systemic nature of their illness. But in
the early 1970s, it became clear that these patients tolerated
hemodialysis treatment as well as did patients with non-SLE renal
diseases [130]. Survival rates for patients with lupus were initially
lower in some [131], but not all studies [132], however. This
increased mortality rate was mainly due to infections secondary to
continued immunosuppressive treatment. At present, the five-
year survival rate of SLE patients treated with dialysis is at least as
good as that for the non-lupus population, and ranges between
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Fig. 5. Actuarial patient survival of 55 SLE patients who progressed to
end-stage renal failure (ESRF pos) compared with that of 92 SLE patients
who did not develop end-stage renal failure (ESRF neg). The survival
curves were not significantly different. Time point zero represents the
onset of lupus nephritis. (Reproduced with permission from Ref. 126.)
80% and 90% [127, 128]. Because the prognosis during dialysis
treatment is relatively so good in patients with SLE, it is no longer
necessary to prevent ESRF at all costs in patients with already
impaired renal function. Although intensification of immunosup-
pression decreased the cumulative incidence of ESRF in some
studies, it did not improve patient survival rates [104, 133].
Actually, in the lupus nephritis studies by the Dutch Working
Party on SLE, patient survival calculated from the onset of lupus
nephritis was similar for patients with lupus nephritis who did
(n = 55) or did not (n = 92) reach ESRF (Fig. 5) [126]. These
data clearly show that dialysis is not associated with a higher
mortality when compared to aggressive therapy of far advanced
lupus.
What is the influence of dialysis on lupus disease activity?
Before addressing this question, we should note that sometimes it
is difficult to determine whether a certain condition (for instance,
pericarditis) is an ESRF-related manifestation or an expression of
lupus disease activity. Given this limitation, we can say that
disease activity generally decreases during dialysis, although dis-
ease manifestations can persist or even develop, especially in the
first year after the start of dialysis [1261. Nossent and colleagues
compared in 55 SLE patients undergoing dialysis treatment—
either hemodialysis (n 32) or CAPD (n = 23)—the maximal
non-renal SLEDAI scores before and after the start of dialysis,
and found that this score decreased significantly (P < 0.001) after
dialysis was started [128]. In 49% of the patients, maximal
non-renal disease activity decreased, in 42% remained stable, and
only in 9% showed progression [128]. No differences were found
between patients treated with hemodialysis or CAPD. The SLE-
DAI is the most sensitive index for measuring changes in SLE
disease activity over time [134J. Nossent et al used another
estimate of disease activity, the time-adjusted event rate of
specific disease manifestations, and discerned no significant dif-
ferences in disease activity between the periods before and after
the start of dialysis, although the events during dialysis occurred
during minimized immunosuppression [128]. For instance, aza-
thioprine or cyclophosphamide administration was stopped in
Table 2. Percentage of SLE patients with glomerulonephritis
developing end-stage renal failure (ESRF) during the last four decadesa 100 -
80
60
40
>
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Table 3. Factors associated with an increased risk for the development
of end-stage renal failure in SLE
÷ ESRF pos
ESRF neg J
Time after transplantation, months
Fig. 6. Graft (solid lines) and patient (dashed lines) survival after renal
transplantation in SLE patients (n = 165) compared with patients with
non-SLE glomerular diseases (n = 21726); 1984—1992. Only first trans-
plants with a cadaveric donor kidney were used for this analysis. Both the
graft and patient survival were not significantly different between the two
groups. (Data were generously provided by Dr. Guido Persijn, Eurotrans-
plant, Leyden, the Netherlands.)
90% of the patients, and the prednisone dose was considerably
reduced in 55%.
Renal transplantation. The patient presented in this Forum did
very well after renal transplantation. She had only a borderline
acute graft rejection three months after transplantation and no
major lupus manifestations during a followup of 4 years. Is her
course a fair general representation of all lupus patients after
renal transplantation? In our Dutch survey on renal transplanta-
tion in lupus patients, both the one- and three-year graft survival
was 68%, and patient survival was 87% [135]. Graft survival was
somewhat lower than that generally achieved nowadays. However,
patient data were collected over an eight-year period, from 1980
to 1988, and one-half of the patients received transplants before
the routine use of cyclosporine A as a basic immunosuppressive
drug. More recent data obtained from Eurotransplant show that
graft and patient survival rates for SLE patients after renal
transplantation are not significantly different from those for
patients with non-SLE glomerular diseases (Fig. 6). Similar results
have been reported in the literature [136—138].
What happens to SLE disease activity after renal transplanta-
tion? In general, disease activity declines further. In the Dutch
analysis, the majority of patients (72%) had no disease activity
after renal transplantation, as judged by SLEDAI scores every
three months during a median followup of 31.5 months (range,
3—89 months) [135]. Figure 7 compares disease activity (using
maximal non-renal SLEDAI scores) before dialysis, during dialy-
sis, and after renal transplantation in SLE patients. It is interest-
ing that high lupus disease activity before or after the start of
dialysis, a duration of dialysis of less than 12 months, or a high
antilymphocyte reactivity before transplantation did not adversely
affect graft survival. In only one patient was a recurrence of the
original disease diagnosed. In a recent survey of the literature, 5
of 321 patients showed recurrence of lupus nephritis after renal
transplantation [126]. If this total number is corrected for the
patients who lose their grafts within the first year, the calculated
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Fig. 7. Lupus disease activity in 28 SLE patients who received a renal
allograft. Disease activity was assessed by the maximal non-renal SLEDAI
before (•) and during () dialysis and after renal transplantation (E).
The SLEDAI scores were divided in three groups: 0, no disease activity;
1—10, moderate disease activity; and >10, high disease activity. Note that
prior to dialysis none of these patients had absent disease activity, but after
renal transplantation none of the patients had high disease activity.
(Figure drawn from data published in Ref. 135.)
cumulative incidence of recurrent disease is 1.9%. This experience
contrasts with a report from Nyberg and colleagues, who found
signs of recurrence in electively taken transplant biopsy specimens
in 7 of 16 SLE patients (43%) [139]. The choice of the parameters
they used to define recurrence—namely, mesangial proliferation
and deposition of 1gM and C3—is debatable, because these
features are not specific for lupus nephritis, especially in trans-
plant biopsies. Thus, most of the literature suggests that in
general, lupus patients have a reduction of disease manifestations
and a very low risk of recurrence after transplantation. It remains
intriguing why these patients respond so well after transplanta-
tion, since they are usually treated with the same kind of drugs
that failed to control their disease before transplantation. In
summary, dialysis and renal transplantation are good treatment
modalities for SLE patients with ESRF. During renal replacement
therapy, lupus disease activity generally subsides, and the likeli-
hood of recurrence of lupus nephritis after renal transplantation is
low.
QUESTIONS AND ANSWERS
DR. Njcoi.&s E. MADIAS (Chief Division of Nephrology, New
England Medical Center, Boston, Massachusetts): What do we
know about the nature of the nucleosomal epitopes that appear to
drive the autoimmune response in systemic lupus erythematosus?
DR. BERDEN: This is an important question. Since it is difficult
to analyze these epitopes with polyclonal auto-antibodies, we and
others have tried to circumvent this problem by analyzing the
antigen specificity of different nucleosome-specific monoclonal
antibodies [151—154]. These analyses revealed that H2A-H2B/
DNA seems to harbor the major epitopes and, to a lesser extent,
also H3-H4/DNA. Time studies, mainly in lupus mice, indicate
that antibodies to H2A-H2B/DNA are formed earlier in the
disease than are those against H3-H4/DNA [26, 55]. We also
tested these monoclonal antibodies on 53 partly overlapping
synthetic peptides, covering all histone proteins, and found with
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one exception (peptide 83—100 from histone H3) no or only very
low reactivity; thus, linear epitopes probably are not very impor-
tant [60, 151]. Because some of these monoclonal antibodies react
better with the total nucleosome than with subnucleosomal struc-
tures, additional epitopes might exist that are still undiscovered
[151]. These data confirm previous observations that nucleosome-
specific antibodies recognize conformational epitopes created by
the interaction between DNA and histones. Relevant epitopes
might not be expressed by native nucleosomes but are only
presented on altered nucleosomes. These alterations (protein
modification/fragmentation) can be induced by oxygen radicals
produced during aberrant apoptosis [47, 481. These novel
epitopes, not expressed on native nucleosomes, are then recog-
nized by T-cells. At the moment we are probing these possibilities
by using nucleosomes released from normal and lupus-derived
apoptotic cells as antigenic targets. This investigation might
elucidate the driving epitope within the nucleosome. Recently
Datta's group localized three regions in the core histones 10—33
H2B, 16—39 H4, and 71—94 H4 that acted as epitopes for
pathogenic T-helper cells [155].
DR. MADIAS: As you know, Madaio and coworkers have isolated
a number of monoclonal antibodies with anti-DNA activity from
various murine models of SLE [15]. These antibodies exhibit
differences in their level of nephritogenicity. Further, individual
nephritogenic antibodies consistently display a distinct pattern of
glomerular injury. Could you please reconcile these observations
with the nucleosomal theory?
DR. BERDEN: We think that these observations are due to the
fact that these monoclonal antibodies are complexed to a variable
degree to nucleosomes, depending on the specificity of the
monoclonal antibody and the hybridoma culture conditions. As
we have shown, it is sometimes very difficult to remove all the
complexed nucleosomal material [211. After purifying anti-nu-
clear monoclonal antibodies and carefully checking for remaining
nucleosomal impurities (with 32P radiolabeling to detect DNA
and agarose gel electrophoresis with double silver staining to
detect histones), we never found glomerular localization with
purified antibodies [21]. Also, cross-reactive binding of monoclo-
nal anti-nuclear antibodies to other non-DNA antigens like
heparan sulfate was abrogated by this purification [17]. The
observation from Dr. Madaio's group that such a cross-reactivity
[14] is a distinguishing feature of their nephritogenic monoclonal
antibodies [156, 157] strongly, albeit indirectly, indicates that
complex formation with nucleosomes is instrumental for induc-
tion of glomerular deposits.
Another line of evidence indicates that Madaio's monoclonal
antibody preparations are complexed to nucleosomes. These
investigators reported that several of their monoclonal antibodies
are able to penetrate cells and to localize into the nucleus [158].
We [159] and others [160] have shown recently that this intracel-
lular uptake of autoantibodies critically depends on the presence
of nucleosomal material bound to the antibody, since purified
antibodies did not bind and were not internalized. In our hands,
the observed nuclear localization was a fixation artifact; if we
prepared the kidney with perfusion-fixation with PLP (periodate
lysine-paraformaldehyde) instead of using tissue fixation with
acetone, we found not nuclear but cytoplasmic localization,
similar to that observed with confocal laser microscopy in living
cells [159]. Although this in-vivo ANA phenomenon is artifactual,
we agree with Dr. Madaio and his coworkers that the induction of
glomerular deposits is characteristic for pathogenic and nephrito-
genie autoantibodies, because it is displayed by autoantibodies
complexed to nucleosomes. These same nucleosome-complexed
autoantibodies can bind to the GBM in vivo [211 and are related
to the onset [161] and exacerbation [162] of lupus nephritis in
patients with SLE. Also, Ohnishi and colleagues concluded that
pathogenic anti-DNA antibodies can: (1) bind to the GBM via
histone/DNA (nucleosomes), and (2) display an in-vivo ANA
phenomenon after acetone tissue fixation [163].
So, to summarize a long answer, both our and Dr. Madaio's
results are consistent with the fact that certain anti-nuclear
antibodies can induce glomerular deposits, but our explanations
for this glomerular binding differ. They attribute their observa-
tions to direct cross-reactive binding of monoclonal antibodies to
the GBM and cell-surface constituents; we have convincing evi-
dence that these reactivities are mediated by nucleosomes.
DR. BEHROOZ BROUMAND (Professor of Medicine, University of
Medical Sciences of Iran, Teheran, Iran): I have three questions.
First, after transplantation most patients with SLE are treated
with prednisone, azathioprine, and cyclosporine. Moreover, after
renal transplantation, disease activity generally declines. Maybe it
would be wise to formally study these drugs to evaluate whether
they are better than either prednisone and cyclophosphamide or
prednisone and azathioprine for the treatment of lupus nephritis.
Second, do you think that ACE inhibitors could be used in the
treatment of lupus nephritis? Besides decreasing blood pressure,
they could reduce proteinuria and prevent further tubulo-inter-
stitial damage. Finally, do you see any future for gene therapy—
for instance, manipulating Bcl-2 or BAX expression in order to
influence apoptosis?
DR. BERDEN: To answer your first question, only limited
experience, in uncontrolled studies, with cyclosporine in the
treatment of class-IV or class-V lupus nephritis has been re-
ported, and the results are not very convincing [164, 165]. What
worries me about the use of cyclosporine for the treatment of
lupus nephritis is that it has no effect on autoantibody formation
either in humans [164] or in spontaneous murine lupus models
[166]. And as mentioned, repeat biopsies during treatment with
cyclosporine showed progression of histologic abnormalities [95]
despite the fact that proteinuria declined. In my opinion, there is
no place for cyclosporine in the treatment of lupus nephritis. You
are correct that disease activity declines after renal transplanta-
tion in the majority of patients, but improvement has already
begun during dialysis and before transplantation. Thus the "burn-
out" of the disease is not due to post-transplant immunosuppres-
sion, but rather originates during dialysis. There is no satisfactory
explanation for this "burn-out."
Your second question relates to the use of ACE inhibitors in
patients with lupus nephritis. It's certainly true that inadequate
blood pressure control in patients with lupus nephritis will
quicken the deterioration of renal function. I am not aware of any
study in lupus patients showing that ACE inhibitors are superior
in this respect to beta-blockers or calcium-entry blockers, We do
know that ACE inhibitors reduce proteinuria [167] and thus could
slow the progression of tubulo-interstitial damage [168]. Austin et
a! recently showed that, indeed, tubulo-interstitial lesions, as in
other glomerular diseases [169], are strong predictors for the
development of end-stage renal failure [143]. Any measure that
reduces this interstitial burden is therefore beneficial.
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Your last question related to gene therapy. I do not think that
gene treatment to influence Bcl-2 expression is currently feasible,
because the margins for this approach seem rather small. In
experimental animals, transgenic overexpression of Bcl-2 lead to
auto-immunity [38]; in Bcl-2 knockout mice, a dramatic involution
of the immune system is observed soon after birth [170, 171]. In
my opinion a more realistic approach would be a search for
nucleosome-derived peptides that could "turn off" the pathogenic
auto-immune response. A similar approach has been successful in
a number of auto-immune models, such as adjuvant-induced
arthritis [172].
DR. MARIAN KLINGER (Professor of Renal Medicine, Department
of Nephrology, University School of Medicine, Wroclaw, Poland):
Your point against cyclophosphamide was very strong, but cyclo-
phosphamide toxicity very much depends on cumulative doses.
Why not start with intravenous cyclophosphamide, administer
doses of, let's say, up to 100 mg/kg, and later support the
remission with azathioprine? One remark: I noticed that the
prednisone dose in your prospective protocol, 1 mg/kg, is higher
than the dose of 0.5 mg/kg used in the original NIH protocol, so
the risk of undesired prednisone effects is greater. Finally, you did
not mention in your choices of therapy so-called "synchronized
plasmapheresis." Do you believe that it is worth a trial?
DR. BERDEN: I did not understand your first point. Did you
propose to give cyclophosphamide at 100 mg/kg?
DR. KLJNGER: I propose to start with standard intravenous
cyclosphamide doses and administer it until a cumulative dose of
100 mg/kg—which is, I believe, without major long-term toxici-
ty—is reached and later try to support the remission with azathio-
prine.
DR. BERDEN: The protocol that you describe with initial cyclo-
phosphamide and subsequent azathioprine has been used by a
number of groups both for lupus and non-lupus glomerular
diseases [122, 173]. Your presumption is that cyclophosphamide
treatment is better, but you want to reduce the side effects. I think
the NIH data force us to conclude that cyclophosphamide is not
superior to azathioprine. So I don't believe that a six-month
induction treatment, which does not exceed the cumulative dose
you mentioned, is advantageous over the combination of intrave-
nous methylprednisolone and azathioprine. Still, we have no
controlled data to support either your or my approach.
You asked about the predisone dose. The two publications
from the NIH group are not very specific about the prednisone
dose they use [103, 104]. The different reports use between 0.5
mg/kg and 1 mg/kg, but in general they did start with 0.5 mg/kg.
However, in our protocol, we taper the dose rapidly, and our
cumulative cyclophosphamide dose is lower (24 months of treat-
ment instead of 30 months).
Your last question about synchronized plasmapheresis is very
current. In 1990 the group of Euler in Kiel started a trial using
synchronized plasmapheresis and cyclophosphamide. The results
have not yet been published, but I recently heard that they will
become available soon. Theoretically, this approach is attractive,
because plasmapheresis stimulates the B-cell, which makes it
more susceptible to the cytotoxic drug given subsequently. We
have to wait for the results of this trial before coming to any
conclusions about this approach.
DR. MADIAS: Some cases of lupus are accompanied by a
thrombotic vasculopathy with glomerular and vascular thrombi,
often in association with a lupus anticoagulant, the clinical picture
being akin to that of thrombotic thrombocytopenic purpura. Are
you of the opinion that plasmapheresis with plasma infusion
should not be used even in that setting?
DR. BERDEN: Some lupus patients do have renal vascular
abnormalities in conjunction with anti-phospholipid antibodies. In
general no correlation exists between the presence of anti-
phospholipid antibodies and the development of lupus nephritis
[174, 175] but, as you said, thrombi can develop in the renal
vasculature [175, 176]. No data regarding optimal treatment are
available; all reports have been anecdotal. We treat these patients
with oral anticoagulants. We don't treat them differently with
regard to the immunosuppressive regimen unless glomerulone-
phritis is absent. These patients, who do not have inflammatory
glomerular lesions, sometimes present with acute renal failure,
often accompanied by malignant hypertension. This condition has
been called the "catastrophic anti-phospholipid syndrome" [177].
Plasmapheresis combined with adequate anticoagulation is cur-
rently the treatment of choice for these patients [177].
DR. S. C. DASH (Professor of Nephrology, All India Institute of
Medicine Sciences, New Delhi, india): Do you use a threshold value
for the histologic activity and/or chronicity index above which you
start treatment with cytotoxic drugs?
DR. BERDEN: We base our decision for treatment with cytotoxic
immunosuppressive agents only on the World Health Organiza-
tion classification (either class III or IV), although the WHO
classification does correlate with the NIH scoring system. In our
retrospective analysis [142], we found a mean activity and chro-
nicity index, respectively, for class III of 4.6 and 3.2, and for class
IV of 8.1 and 3.9; for class II and V, these indices were much
lower. Of course, it would be nice to have the results of a study in
which you could further refine your therapy based on histologic
criteria like the activity and chronicity indices. But it will be very
difficult to perform a study in which patients are stratified
according to NIH activity and chronicity indices. It is difficult
enough to carry out a trial based on the WHO classification, as
evidenced by the low number of controlled studies available. The
only situation in which we take the NIH score into account is if the
patient has advanced sclerotic glomerular lesions and a high
chronicity index. The majority of these patients are categorized as
WHO class VI. We are reluctant to prescribe cytotoxic drugs in
this group because we don't anticipate much of a functional
benefit.
DR. Mi VENNING (Consultant Renal Physician, Withington
Hospital, University Hospital of South Manchester, Manchester,
England): I am concerned that you might have drawn some
conclusions that are not fully warranted by the evidence, specifi-
cally with reference to the size of the trials and a lack of power to
support negative conclusions. From conversations a few years ago
with Dr. Balow, I understand that he believes cyclophosphamide
to be a better therapy than azathioprine for lupus nephritis.
Further, clinical experience with patients who have responded to
cyclophosphamide after having relapsed or failed to achieve
control with azathioprine therapy also suggests that active lupus
nephritis is better treated with cyclophosphamide. The NIH study
did not have sufficient power to determine whether cyclophospha-
mide is better than azathioprine.
Similarly, clinical experience with chronic ambulatory perito-
neal dialysis (CAPD) in lupus patients suggests that the risk of
peritonitis or exit-site infection is high following immunosuppres-
sion, particularly when high doses of steroids have been used. I am
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concerned that sufficient data are not available to demonstrate the
equivalent effectiveness of hemodialysis, which I believe to be
better in this setting, and CAPD.
DR. BERDEN: I cannot exclude the possibility that the NIH
studies are flawed by a class-Il error, especially because the
number of patients treated with azathioprine was rather small.
But studies other than the NIH investigation have shown no
conclusive differences between azathioprine and cyclophospha-
mide in the treatment of lupus nephritis [99, 100]. Actually, in the
meta-arialysis by Felson and Anderson, azathioprine preserved
renal function better, and was associated with a lower number of
deaths due to non-renal causes, than did cyclophosphamide [1001.
Indeed, although our NIH colleagues advocate cyclophosphamide
therapy, their results do not prove that cyclophosphamide treat-
ment is better.
Your second comment suggested that hemodialysis is better
than CAPD in patients with lupus. Clearly, CAPD bears the
intrinsic risk of peritonitis and exit-site infections, possibly due to
immunosuppression. But as I said, our policy—and I think that
this is true for most clinics—is to reduce immunosuppression as
soon and as quickly as possible. With this policy we have not
observed any difference in our comparison between hemodialysis
(n = 32) and CAPD patients (n = 23) in terms of survival, lupus
disease activity, and complications. The incidence of peritonitis in
lupus patients did not differ significantly from that in the non-
lupus population. Cheigh et al came to the same conclusion [178].
DR. VENNING: But again this might be subject to a class-Il error
and perhaps needs further study.
DR. BERDEN: Maybe, but to my knowledge our study is the
largest study available.
DR. SANDOR SONKODI (Professor of Medicine and Nephroloy,
First Department of Medicine, Albert Szent-Györgyi Medical Univer-
sity, Szeged, Hungaiy): May I go back to the question of cytotoxic
treatment? In your opinion, what is the value of chlorambucil in
the treatment of lupus nephritis? As you know, chiorambucil has
fewer side effects than cyclophosphamide.
DR. BERDEN: I don't know whether it is true that chlorambucil
has fewer side effects than cyclophosphamide. Furthermore, there
are no solid data available about the efficacy of this drug in the
treatment of lupus nephritis [164, 179]. Although we do not have
experience with chlorambucil in lupus nephritis, it has been used
in our department for the treatment of idiopathic membranous
glomerulonephritis [93]. In this prospective trial, in which we
compared chlorambucil with cyclophosphamide given intrave-
nously, patients did not have fewer side effects with chiorambucil
than with cyclophosphamide. So I prefer cyclophosphamide over
chiorambucil. But again, there are no controlled studies compar-
ing these two drugs in lupus nephritis.
DR. M1As: Do you envision a role for newer drugs, such as
rapamycin, mycophenolate, or FK506, in the management of
lupus nephritis?
DR. BERDEN: Of the drugs you mentioned, I think mycopheno-
late has the best potential. It has a much more profound effect on
antibody production by B-cells than does azathioprine or cyclo-
phosphamide. If the formation of autoantibodics is instrumental
for the development of the different tissue lesions, this effect
might be an important advantage. In addition, mycophenolate has
anti-inflammatory effects, mainly because it inhibits the recruit-
ment of neutrophils, lymphocytes, and monocytes to the inflam-
matory site [180, 181]. Rapamycin and FK506 are also potentially
interesting drugs, although their effects on antibody production
are less well established. All three drugs have shown beneficial
effects on the autoimmune disease in MRL/lpr and (NZBxW)F1
lupus mice [182—1841.
DR. MADIAS: How do you manage patients whose disease is
resistant to conventional therapy?
DR. BERDEN: It depends on the degree of renal function and the
previous treatment. If the patient has received several courses of
induction treatment with immunosuppressive drugs, has poor
renal function, and a renal biopsy shows extensive chronic lesions,
we prepare the patient for dialysis and renal transplantation. New
cases are currently enrolled in the Dutch prospective trial com-
paring cyclophosphamide pulses with intravenous methylpred-
nisolone, low-dose oral prednisone, and azathioprine. If it is a first
manifestation or a first flare and the patient fails to respond, we
switch to the other arm of our protocol. Before we started this
prospective trial, we added plasmapheresis to the treatment of
resistant cases, but after the results of the plasmapheresis trial
became available [1221, we stopped doing so.
DR. BHARAT V. SHAH (Head of Nephrology Section, P.D. Hinduja
National Hospita4 Mumbai, India): You reserve treatment with
cytotoxic drugs mainly for patients with class-Ill and class-IV
lupus nephritis. Don't you think that a class-Il nephritis can
progress to class-Ill or -IV, and that by giving cytotoxic treatment
one can prevent this progression?
DR. BERDEN: You are right that transition from class-Il to
class-Ill or -IV has been documented [41. However, this transition
is generally accompanied by a worsening of clinical signs and
symptoms—either the appearance of a nephritic sediment, an
increase in or reappearance of proteinuria, deterioration of renal
function, or hypertension. So one should monitor a patient with
class-Il lupus nephritis for these changes. If the patient's clinical
status does decline, a repeat renal biopsy is indicated to document
whether class-Ill or -IV disease has developed. If this is the case,
treatment with cytotoxic drugs should be started. Prescription of
cytotoxic drugs to every patient with class-TI lupus nephritis leads
to overtreatment in the majority of these patients; the greatest
proportion respond adequately to prednisone monotherapy.
DR. FERNANDO VALDERRABANO (Professor of Medicine, Head,
Department of Nephrology, Hospital General Universitario Gregorio
Maranón, Madrid, Spain): You showed clearly that lupus activity
decreases in patients with SLE when they develop end-stage renal
disease, a decrease probably owing to depression of the immune
response in severe renal failure. On the other hand, treatment
with recombinant human erythropoietin can improve the immune
response in patients with end-stage renal disease [185, 186]. In
your experience, does erythropoietin therapy reactivate disease
activity in lupus patients undergoing dialysis?
DR. BERDEN: I have never seen this in our patients, nor am I
aware of such an observation in the literature. Has anyone in the
audience had such an experience?
DR. VALDERRABANO: We have monitored five hemodialysis
patients in whom lupus nephritis was the primary renal disease.
Erythropoietin therapy did not stimulate disease activity in any of
them; followup was 6 to 36 months. Also, a 1994 report from
Hebert et al found that administration of recombinant erythro-
poietin did not alter serologic parameters (C3 levels, ANA,
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anti-dsDNA), or clinical disease markers (serum creatinine, uri-
nalysis, proteinuria) in five SLE patients who had slightly im-
paired renal function (serum creatinine 150 mol/liter, 1.7 mg/dl)
[187].
DR. K.S. NAYAK (Chi ef of Nephrology, Appollo Hospitals, Hyder-
abad, India): You said that you performed a renal biopsy in your
patient initially, and you found a low chronicity index and a veiy
high activity index. Why did you not repeat the biopsy, especially
before transplantation?
DR. BERDEN: We have one prerequisite for performing a repeat
biopsy: the results of that biopsy should have therapeutic conse-
quences. If you already are using the most extensive treatment
protocol, a repeat biopsy is indicated only if you plan to stop the
treatment if extensive chronic lesions (WHO class VI) are found.
Our patient did not want to continue extensive immunosuppres-
sive treatment after her fourth renal flare. She accepted the
eventual development of end-stage renal disease, and hoped for
successful renal transplantation, as a living kidney donor was
available. In this instance, a repeat biopsy thus would have had no
therapeutic consequences.
DR. DIMITRI0s GREKAS (Associate Professor of Nephrology,
University HospitalAhepa, Thessaloniki, Greece): Do you continue
the every-three-month pulse therapy with intravenous cyclophos-
phamide for a finite number of years or indefinitely?
DR. BERDEN: In the Dutch protocol, it is continued for two
years in total. We give the cyclophosphamide every month for six
months, and then administer it every 3 months for 18 months. In
the NIH protocol, these intravenous cyclophosphamide pulses are
given for a maximum of 30 months [115]. Because the side effects
of cyclophosphamide, especially its carcinogenic potential,
urothelial cell toxicity, and risk of infertility, are related to the
cumulative dose [108, 112], my advice would be not to exceed a
treatment period of 30 months.
DR. GREKAS: What is your view concerning pregnancy in a
young woman with SLE nephritis?
DR. BERDEN: I do not have the time in this Forum to present a
balanced view on this topic. We would have to take into account
all the different aspects, such as the effect of pregnancy on SLE,
the effect of SLE on pregnancy, the impact of the anti-phospho-
lipid syndrome on pregnancy, the neonatal lupus syndrome, and
the consequences of pregnancy for immunuosuppressive treat-
ment and vice-versa. This discussion by itself could be the subject
of a Nephrology Forum. So let me offer our general policy, which
is more or less identical to that for women with other non-lupus
renal diseases. If the SLE is serologically and clinically inactive,
the patient has good renal function, a normal blood pressure, and
no nephrotic-range proteinuria, we do not think that pregnancy is
contraindicated. But if her disease is active, the serum creatinine
exceeds 150 tmol/liter (1.7 mg/dI), or hypertension is present, we
strongly advise the patient not to become pregnant. Historically,
physicians have feared that pregnancy or delivery will reactivate
SLE. But a recent review concluded that the number of patients
who experienced a disease flare during pregnancy is very low if the
disease is inactive at conception [1881.
DR. MAHER RAJvIzY (Professor of Renal Medicine, Cairo Univer-
sity, Cairo, Egypt): In your opinion, what is the most sensitive
serologic marker for disease monitoring, ANA, anti-dsDNA, C3,
or C4? My second question is: is there a difference in lupus
between male and female patients?
DR. BERDEN: Reports from the Netherlands by Swaak et al
[189—192] and by ter Borg and coworkers [6] showed that 80% to
90% of the disease flares are preceded by a significant rise in
anti-dsDNA antibodies. These changes were more sensitive than
were changes in complement profiles. These observations suggest
that the anti-dsDNA titer is the best parameter for monitoring the
patient. Of course, changes in C3 and C4 also can be taken into
account, but these markers are less sensitive. As I said earlier,
Kallenberg's group conducted a trial in which treatment was
guided by changes in anti-dsDNA titers [125]. Another serologic
marker that could be of potential interest for monitoring lupus
nephritis is the anti-Clq antibody titer. The same group found
that a rise in anti-Clq preceded a renal flare by 10 weeks [85].
Finally, future research will reveal whether measurement of
nucleosome-specific autoantibodies will provide a better tool for
disease monitoring. In view of the pathophysiologic concept that
I presented, this approach seems promising.
Now let me respond to your second question. In a retrospective
analysis, Miller et a! discerned no differences in disease manifes-
tations, disease severity, or positive family history for autoimmune
diseases when they compared 51 male patients with female lupus
patients [193]. In a more recent review, Kaufmann and colleagues
noted a higher incidence of thrombocytopenia and renal disease
in male lupus patients; all other clinical and serologic parameters
did not differ [194]. As I already mentioned, the risk of developing
ESRF is higher in male patients with lupus nephritis than in
females.
DR. HERMINI0 SuAzo (Nephrologist, Kidney and Hypertension
Center, Houma, Louisiana, USA): According to the case summary,
when the patient's serum creatinine reached 620 tmol/liter (7.0
mg/dl), she was started on a low-protein diet. Would you please
comment on the evidence that dietary protein restriction is
beneficial in nondiabetic patients with chronic renal disease as
opposed to the risk of malnutrition in patients starting dialysis?
DR. BERDEN: The low-protein diet was not prescribed in an
attempt to influence the progression of her renal disease, but
because her urea levels were increasing and we wanted to control
her azotemia. We prescribed 0.8 g of protein/kg body weight, an
amount that generally does not lead to malnutrition.
DR. MARIANO RODRIGUEZ (Associate Professor of Medicine,
Hospital Universitario Reina Sofia, Cordoba, Spain): Let me return
to the question of pathogenesis. You mentioned apoptosis as a
key causative factor in lupus. Has your group or any other group
demonstrated that peripheral blood mononuclear cells show signs
of apoptosis in vitro? If this is the case, could these cells be used
to monitor treatment or detect flares?
DR. BERDEN: As I mentioned earlier, some observations in the
literature point to a disturbed apoptosis in lupus. These include an
increased spontaneous apoptosis in vitro [31, 195], an increased
expression of Bcl-2 in lymphocytes [42] and, although not uni-
formly confirmed [40, 41], increased circulating levels of soluble
Fas [39]. Kalden's group recently reported that phagocytosis of
apoptotic cells was impaired in lupus patients [196]. However,
none of these parameters has yet been evaluated for its diagnostic
or prognostic potential. At present, Dr. Smeenk and colleagues
(CLB, Amsterdam) are performing a prospective study to analyze
the relation between levels of soluble Fas and disease activity.
Their preliminary data indicate that disease flares are preceded,
by as early as 5 months, by an increase of soluble Fas, while in
patients with inactive disease, the levels remain normal. In the
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near future, we will measure the surface expression of phospha-
tidylserine on peripheral blood lymphocytes, as this is one of the
first signs of apoptosis at the cell surface, Other cell-surface
changes that are not yet well-defined [197] also occur on apoptotic
cells. As soon as these changes are elucidated, their significance
for SLE can be probed. Finally, since nucleosome release is a key
feature of apoptosis, measurement of nucleosome autoantibody
complexes in the circulation of SLE patients could form a new
tool for monitoring. This approach is now feasible because
Fournié recently developed a method of measuring these com-
plexes [198].
DR. ZBIGNIEW HRUBY (Associate Professor of Nephrology, Wro-
claw School of Medicine, Wroclaw): I would like to address the
issue of flares or relapses that are refractory to treatment. Do you
think that there is a role for intravenous immunoglobulin for these
severe cases? Yesterday at this EDTA/ERA Congress Dr. Lock-
wood spoke about the therapeutic potential of intravenous immu-
noglobulin for the management of severe ANCA-associated vas-
culitides. Today you mentioned anti-GBM autoantibodies that
could be inhibited by anti-idiotypic antibodies present in these
immunoglobulin preparations.
DR. BuRDEN: Let me first make sure that my message was clear.
No anti-GBM antibodies are present in SLE. In our concept,
autoantibodies are targeted to the GBM, because they are
complexed in the circulation to nucleosomes, thereby gaining
affinity for the GBM. I do not have personal experience with
intravenous immunoglobulin treatment in lupus nephritis. The
literature contains only a few scattered reports on intravenous
immunoglobulin therapy in lupus and no controlled data [199,
200]. In some patients intravenous immunoglobulin therapy had a
brief but positive effect on extrarenal symptoms. Some patients
even experienced an exacerbation of glomerulonephritis [199]. I
do not think that I can recommend this form of treatment on the
basis of these results.
DR. AIDA R. J. Mousuw (Head of Nephrology Service, Hotel-
Dieu de France Hospital Beyrouth, Lebanon): Do you envision a
role for subcutaneously given heparin in the treatment of lupus,
based on your experimental animal data?
DR. BERDEN: In our experimental animal studies, if we started
early with heparin and non-coagulant heparin derivatives, we
could prevent proteinuria and could decrease the severity of the
glomerulonephritis, as assessed by light microscopy and immuno-
fluorescence. However, if we treated animals with already estab-
lished proteinuria and nephritis, we did not observe a reduction in
proteinuria, although the progression of proteinuria slowed. If we
added non-coagulant heparin derivatives to a subtherapeutic dose
of cyclophosphamide, we could prolong survival significantly
compared to that with cyclosphamide treatment alone [70]. How-
ever, at present no data are available for human lupus. It
nevertheless remains an intruiging possibility, moreover because
heparin and heparinoids might have other beneficial effects on
immune-mediated glomerular pathology, including inhibition of
mesangial proliferation and sclerosis, modulation of extracellular
matrix production, inhibition of binding of immune complexes to
mesangial cells (at least in vitro), inhibition of complement
activation, and downregulation of T-cell-mediated responses [70].
DR. MoussALI: I have another question regarding the patient
who was presented. What were the odds of her becoming preg-
nant given the severity of her disease? In my opinion, her disease
was so severe that the odds for her completing a successful
pregnancy were poor. One more question: did she become
pregnant after renal transplantation?
DR. BERDEN: I agree with you that the disease in this patient
was severe; it led to end-stage renal failure within four years. But
a lupus patient with this form of nephritis has an 80% chance of
not developing end-stage renal failure. We were hoping that she
would respond well to the treatment and that she could become
pregnant later if she met the criteria I already mentioned in
response to one of Dr. Grekas' questions. I agree with you that
during her disease her chances for a successful pregnancy were
low, but she rejected cyclophosphamide treatment because of its
risk of inducing infertility. Your second question was about
pregnancy after renal transplantation. The patient, now in good
condition, also raised this question. A search of the literature
revealed only three lupus patients who received transplants and
who later became pregnant [201, 202]. Two of the three patients
carried their pregnancies to term successfully. I think that at the
moment there are no absolute contraindications for pregnancy in
our patient.
DR. Jr J. WEENING (Professor of Pathology, Department of
Pathology, Academic Medical Center, University of Amsterdam,
Amsterdam, The Netherlands): In your discussion on the mecha-
nisms of induction of SLE, you mentioned the possible role of
abnormal apoptosis and the appearance of cryptic epitopes.
Recent studies from Ernst Gleichmann and our own group have
provided evidence that similar mechanisms might be involved in
SLE induced by drugs and heavy metals. As you know, a number
of drugs and heavy metals such as gold and mercuric chloride can
cause SLE in humans and a lupus-like syndrome in laboratory
animals. Gleichmann's group showed that gold can interfere with
protein folding during antigen processing and result in presenta-
tion of cryptic peptides instead of the usual dominant peptides
[203]. The cryptic peptides are not recognized as self and elicit an
autoimmune response. In addition, Aten from our group showed
that mercury can change antigenic peptides in such a way that
T-cell recognition is altered. Furthermore, Aten showed that
mercuric chloride can cause apoptosis in lymphocytes and possibly
lead to immune dysregulation; transfection of the Bcl-2 gene
resulted in a reduction in mercury-induced apoptosis [204].
DR. BuRDEN: Thank you for this comment, which extends the
data that I discussed.
DR. R. Br'xs (Nephrologist, Gloucester Royal Hospital Glouces-
ter, UK): How long would you continue treatment with steroids
and azathioprine in a stable, quiescent patient? Is it a life-long
sentence?
DR. BERDEN: This is a very important question but one that is
difficult to answer. To my knowledge, no controlled studies are
available in which the medication was electively stopped.
Boumpas et a! suggested that quarterly pulses of cyclophospha-
mide should be continued at least one year after remission of
renal disease is reached [205]. However, these authors did not
state whether all medication was stopped. In a retrospective
analysis of 84 SLE patients, Ciruelo and coworkers found that
after cessation of CPM (given either orally or intravenously), the
cumulative incidence of relapse of glomerulonephritis was 25% at
5 years and 46% at 10 years [206]. Risk factors for relapse
included oral treatment with CPM, onset of nephritis before the
age of 29 years, and delay of treatment from onset of nephritis for
more than five months. Similar data are not available for cessation
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of treatment with prednisone and/or azathioprine. In a retrospec-
tive analysis in a relatively small number of patients (n = 25),
Moroni et al found that after a mean followup of 88 months, 11
patients were stable without treatment. The incidence of lupus
flare-ups decreased significantly after the tenth year (0.11 flares!
patient/year versus 0.31 in the years before) [207]. Until recently,
we treated our patients with low (alternate-day) doses of pred-
nisone and azathioprine (1.5 mg/kg) for at least 10 years after
onset of nephritis. In the ongoing Dutch prospective study,
patients in both treatment arms receive after two years 10 mg of
prednisone and 2 mg/kg azathioprine, both of which are continued
for two more years. Thereafter, we taper the medication gradually
using careful monitoring of clinical and serologic (anti-dsDNA,
C3, and C4) parameters. The Dutch study will evaluate the
consequences of this withdrawal policy.
DR. ALEXANDER CROWE (Senior Registrar in Nephrology, Royal
Liverpool University Hospital, Merseyside, UK): The patient in the
presentation received a renal transplant six months after starting
renal replacement therapy and while her serologic markers were
negative. What safety criteria do you use for the timing of
transplantation with respect to lupus?
DR. BERDEN: The general policy is to transplant a kidney 6 to 12
months after the onset of ESRF, in the absence of lupus disease
activity [127, 208]. However, this policy is based on a prudent
approach rather than on hard data. No differences were found for
graft or patient survival between patients who received transplants
within or after three months of dialysis treatment [209]. Also Goss
et al reported no clear benefit from a longer dialysis period [137].
In the Dutch study on transplantation in lupus patients, disease
activity prior to transplantation did not influence patient or graft
survival [1351. It has been suggested, but not unequivocally
proven, that there is an association between pretranspiant positive
lupus serology and recurrence [137]. Therefore our approach is to
wait for at least three months to allow for eventual recovery of
renal function, and to perform transplantation after lupus serol-
ogy has become negative.
Reprint requests to Dr. J.H.M. Berden, Academisch Ziekenhuis Nijmegen
St. Radboud, Division of Nephrology (545), Postbus 9101, 6500 HB Nijme-
gen, The Netherlands
ACKNOWLEDGMENTS
The financial support of the Dutch Kidney Foundation (grants C87.704,
C91.1081, C94.1363, C95.1513) and the Dutch League against Rheuma-
tism (grants 87/CR/70, 9OICR/287, 95.735) is gratefully acknowledged. The
Principal Discussant acknowledges Dr. K.J.M. Assmann (Dept. of Pathol-
ogy, University Hospital, Nijmegen) for histologic analysis of the biopsy
specimens of the presented patient and thanks Drs. J.F.M. Wetzels and
L,H. Hilbrands (Div. of Nephrology, University Hospital, Nijmegen) for
their critical evaluation of the manuscript. The author also thanks Dr. J.C.
Nossent (Dept. of Medicine, Vefsn Hospital, Mosjøen, Norway) and Dr.
G. Ligtenberg (Div. of Rheumatology and Clinical Immunology, Univer-
sity Hospital, Utrecht) for helpful discussions. Expert secretarial assis-
tance was provided by Mrs. Ilse Hilgers-Biermans.
REFERENCES
1. SOLEZ K, AXELSEN RA, BENEDIKTISSON H, BURDICK JF, COHEN AH,
COLvIN RB, CROKER BP, DROZ D, DUNNIL MS, HALLORAN PF,
HAYRY P, JENETTE JC, KEOWN PA, MARCUSSEN N, MIHAT5CH MJ,
MOROZUMIK K, MYERS BD, NAST CC, OISEN S, RACUSON LC,
RAMOS EL, ROSEN S, SACHS DH, SALOMON DR, SANFILLIPO F,
VERANI R, VON WILLEBRAND E, YAMAGUCHI Y: International stan-
darization of criteria for the histological diagnosis of renal allograft
rejection: The Banif working classification of kidney transplant
pathology. Kidney mt 44:411—422, 1993
2. ADLER S, COHEN AH, GLASSOCK RJ: Secondasy glomerular diseases,
in The Kidney, edited by BRENNER BM, Philadelphia, Saunders, 1996,
p 1498
3. CHURG J, BERNSTEIN J, GLASSOCK RJ: Lupus nephritis, in Renal
Diseases. Classification and Atlas of Glomerular Diseases, edited by
CHURG J, BERNSTEIN J, GLASSOCK RJ, New York, Igaku-Shoin, 1995,
p 151
4. KASHGARIAN M: Nephrology Forum: Lupus nephritis: lessons from
the path lab. Kidney mt 45:928—938, 1994
5. T. EM: Antinuclear antibodies: diagnostic markers for autoim-
mune diseases and probes for cell biology. Adv Immunol 44:93—149,
1989
6. TER BORG EJ, HORST G, HUMMEL EJ, LIMBURG PC, KALLENBERG
CGM: Predictive value of rises in anti-double-stranded DNA anti-
body levels for disease exacerbations in systemic lupus erythemato-
sus: a long term prospective study. Arthritis Rheum 33:634—643, 1990
7. K.iuro KC, PANOSIAN-SAHAKIAN N, EBLING FM, COHEN AH,
LOUIE JS, KAINE J, HAHN BH: Idiotypic characteristics of immuno-
globulins associated with systemic lupus erythematosus, Arthritis
Rheum 32:513—522, 1989
8. KOFFLER D, AGNELLO V, THOBURN R, KUNKEL HG: SLE, prototype
of immune complex nephritis in man. J Exp Med 134:169S—179S,
1971
9. EILAT D: Crossreactions of anti-DNA antibodies and the central
dogma of lupus nephritis. Immunol Today 6:123—127, 1985
10. Dzi.siu R: Autoimmunity: Polyclonal activation or antigen induc-
tion. Immunol Today 9:340—342, 1988
11. Izul S, LAMBERT PH, MIESCHER PA: Failure to detect circulating
DNA-anti-DNA complexes by four radioimmunological methods in
patients with systemic lupus erythematosus. Clin Exp Immunol
30:384—392, 1977
12. LAFER EM, RAUCH J, ANDRZEJEWSKI C JR, Muoo D, FURIE B,
SCHWARTZ RS, STOLLAR DB: Polyspecific monoclonal lupus autoan-
tibodies reactive with both polynucleotides and phospholipids. J Exp
Med 153:897—909, 1981
13. FAABER P, RIJKE GPM, VAN DE PUTrE LBA, CAPEL PJA, BERDEN
JHM: Crossreactivity of human and murine anti-DNA antibodies
with heparan sulphate: the major glycosaminoglycan in glomerular
basement membrane. J Clin Invest 77:1824—1830, 1986
14. SABBAGA J, PERES LINE SR, POTOCNJAK P, MADAIO MP: A murine
nephritogenic monoclonal anti-DNA autoantibody binds directly to
mouse laminin, the major non-collagenous protein component of the
glomerular basement membrane. Eur J Immunol 19:137—143, 1989
15. FOSTER MH, CIzMAN B, Ms.DAIO MP: Biology of disease. Nephrito-
genie autoantibodies in systemic lupus erythematosus: immuno-
chemical properties, mechanisms of immune deposition, and genetic
origin. Lab Invest 69:494—507, 1993
16. JACOB L, VIARD JD, ALLENET B, ANIN MF, SIMA FBH,
VANDERKERCKHOVE J, PRIMO J, MARKOVITS J, JACOB F, BACH JF, LE
PECO JB, LOUVARD D: A monoclonal anti-double-stranded DNA
autoantibody binds to a 94-kDa cell-surface protein on various cell
types via nucleosomes or a DNA-histone complex. Proc NatlAcad Sci
USA 86:4669—4673, 1989
17. TERMAAT RM, BRINKMAN K, VAN GOMPEL F, VAN IDE HEUVEL
LPWJ, VEERKAMP J, SMEENK RJT, BERDEN JHM: Cross-reactivity of
monoclonal anti-DNA antibodies with heparan sulfate is mediated
via bound DNA/histone complexes. J Autoimmun 3:531—545, 1990
18. TERMAAT RM, ASSMANN KJM, VAN SON JPHF, DIJKMAN HBPM,
KOENE RAP, BERDEN JHM: Antigen-specificity of antibodies bound
to glomeruli of mice with systemic lupus erythematosus-like syn-
dromes. Lab Invest 68:164—173, 1993
19. CHAN TM, FRAMPTON G, STAINES NA, HOBBY P, PERRY GJ,
CAMERON JS: Different mechanism by which anti-DNA Moabs bind
to human endothelial cells and glomerular mesangial cells. Clin Exp
Immunol 88:68—74, 1992
20. BRINKMAN K, TERMAAT RM, BERDEN JHM, SMEENK RJT: Anti-
DNA antibodies and lupus nephritis: the complexity of crossreactiv-
ity. Immunol Today 11:232—234, 1990
21. KRAMERS C, HYLKEMA NM, VAN BRUGGEN MCJ, VAN DE LAGEMAAT
R, DIJKMAN HBPM, ASSMANN KJM, SMEENK RJT, BERDEN JHM:
Anti-nucleosome antibodies complexed to nucleosomal antigens
554 Nephrology Fomm: Lupus nephritis
show anti-DNA reactivity and bind to rat glomerular basement
membrane in vivo. J Clin Invest 94:568—577, 1994
22. DIAMOND B, KATZ JB, PAUL E, ARANOW C, LUSTGARTEN D,
SCHARFF MD: The role of somatic mutation in the pathogenic
anti-DNA response. Annu Rev Immunol 10:731—757, 1992
23. CARSON DA: The specificity of anti-DNA antibodies in systemic
lupus erythematosus. J Immunol 146:1—2, 1991
24. BERDEN JHM: Nucleosomes and lupus nephritis, in Lupus Nephritis,
edited by LEwIs EJ, Oxford, Oxford University Press, in press
25. REEVES WH, SATOH M, WANG J, CHOU CH, AJMANI AK: Antibodies
to DNA, DNA-binding proteins, and histones. Rheum Dis Clin North
Am 20:1—28, 1994
26. BURLINGAME RW, B0EY ML, STARKEBAUM G, RUBIN RL: The
central role of chromatin in autoimmune responses to histones and
DNA in systemic lupus erythematosus. J Clin Invest 94:184—192, 1994
27. TA.x WJM, KRAMERS C, VAN BRIJGGEN MCJ, BERDEN JHM: Apo-
ptosis, nucleosomes, and SLE nephritis. Kidney lot48:666—673, 1995
28. RUMORE PM, STEINMAN CR: Endogenous circulating DNA in sys-
temic lupus erythematosus. Occurrence as multimeric complexes
bound to histone. J Clin Invest 86:69—74, 1990
29. COHEN J: Apoptosis. Immunol Today 14:126—130, 1993
30. SAVILL J, FADOK V, HENSON P, HASLETIT C: Phagocyte recognition of
cells undergoing apoptosis. Immunol Today 14:131—136, 1993
31. EMLEN W, NIEBUR J, KADERA R: Accelerated in vitro apoptosis of
lymphocytes from patients with systemic lupus erythematosus. J Im-
munol 152:3685—3692, 1994
32. MOUNTZ JD, ZHOU T, Wv J, WANG W, Su X, CHENG J: Regulation
of apoptosis in immune cells. J Clin Immunol 15:1—16, 1995
33. WATANABE-FUKUNAGA R, BRANNAN CI, COPELAND NG, JENKINS
NA, NAGATE S: Lymphoproliferation disorder in mice explained by
defects in Fas antigen that mediates apoptosis. Nature 356:314—317,
1992
34. SINGER GG, CARRERA AC, MARSHAK-ROTHSTEIN A, MARTINEZ AC,
ABBAS AK: Apoptosis, Fas and systemic autoimmunity: the MRL/lpr
model. Curr Opin Immunol 6:913—920, 1994
35. NAGATA S, SUDA T: Fas and Fas ligand: lpr and gld mutations.
Immunol Today 16:39—43, 1995
36. Wv J, Zi-iou T, ZHANG J, HE J, GAUSE WC, MOUNTZ JD: Correction
of accelerated autoimmune disease by early replacement of the
mutated lpr gene with the normal Fas apoptosis gene in the T cells
of transgenic MRL-lpr/lpr mice. Proc Nati Acad Sci USA 91:2344—
2348, 1994
37. Nisn 5, TSUBATA T, MURAKAMI M, OKAM0T0 M, HONJO T: The
bcl-2 gene product inhibits clonal deletion of self-reactive B lympho-
cytes in the peripheiy but not in the bone marrow. J Exp Med
178:1247—1254, 1993
38. STRASSER A, WHITrINGHAM S, VAUX DL, BATH ML, ADAMS JM,
CORY S, HARRIS AW: Enforced bcl-2 expression in B-lymphoid cells
prolongs antibody responses and exhibits autoimmune diseases. Proc
NatlAcad Sci USA 88:8661—8665, 1991
39. CHENG J, ZHOU T, Liv C, SIi.pIRo JP, BRAvER MJ, KIEFER MC,
BARR PJ, MOUNTZ JD: Protection from Fas-mediated apoptosis by a
soluble form of the Fas molecule. Science 263:1759—1762, 1994
40. GOEL N, ULRICH DT, Sr CLAIR EW, FLEMING JA, LYNCH DH,
SELDIN MF: Lack of correlation between serum soluble Fas/APO-1
levels and autoimmune disease. Arthritis Rheum 38:1738—1743, 1995
41. KNIPPING E, KRAMMER PH, ONEL KB, LEHMAN TJA, MYSLER E,
ELK0N K: Levels of soluble Fas/APO-1/CD95 in systemic lupus
erythematosus and juvenile rheumatoid arthritis. Arthritis Rheum
38:1735—1737, 1995
42. ARINGER M, WINTERSBERGER W, STEINER CW, KIENER H, PRESIERL
E, JAEGER U, SMOLEN JS, GRANINGER WB: High levels of bcl-2
protein in circulating T lymphocytes but not B lymphocytes, of
patients with systemic lupus erythematosus. Arthritis Rheum 37:1423—
1430, 1994
43. MARRACK P, HUGO P, MCCORMACK I, KAPPLER J: Death and T cells.
Immunol Rev 133:119—129, 1993
44. MERYHEW NL, SHAVER C, MESSNER RP, RUNQUIST OA: Mononu-
clear phagocyte system dysfunction in murine SLE: abnormal clear-
ance kinetics precede clinical disease. J Lab Clin Med 117:181—193,
1991
45. ROBEY FA, JONES KD, STEINBERG AD: C-reactive protein mediates
the solubilization of nuclear DNA by complement in vitro. J Exp Med
161:1344—1356, 1985
46. ROBEY FA, JONES KD, TANAKA T, Liv TY: Binding of C-reactive
protein to chromatin and nucleosome core particles. A possible
physiological role of C-reactive protein. J Biol Chem 259:7311—7316,
1984
47. CASCIOLA-ROSEN LA, ANHALT G, ROSEN A: Autoantigens targeted
in systemic lupus erythematosus are clustered in two populations of
surface structures on apoptotic keratinocytes. J Exp Med 179:1317—
1330, 1994
48. CASCIOLA-ROSEN LA, ANHALT G, ROSEN A: DNA-dependent pro-
tein kinase is one of a subset of autoantigens specifically cleaved
early during apoptosis. J Exp Med 182:1625—1634, 1995
49. SUENAGA R, ABD0u NI: Anti-(DNA-histone) antibodies in active
lupus nephritis. J Rheumatol 23:279—285, 1996
50. BELL DA, MORRISON B, VANDENBYGARRT P: Immunogenic DNA-
related factors. Nucleosomes spontaneously released from normal
murine lymphoid cells stimulate proliferation and immunoglobulin
synthesis of normal mouse lymphocytes. J Clin Invest 85:1487—1496,
1990
51. MOHAN C, ADAMS 5, STANIK V, DArrA SK: Nucleosome, a major
immunogen for pathogenic autoantibody-inducing T cells of lupus. J
Exp Med 177:1367—1381, 1993
52. MAMULA MJ: Lupus autoimmunity: from peptides to particles.
Immunol Rev 144:301—314, 1995
53. BERDEN JHM, SMEENK RJT: Nucleosome-specific auto-antibodies,
in Autoantibodies, edited by PETER JB, SHOENFELD Y, Amsterdam,
Elsevier, 1996, p 574
54. CHABREH, AMOURA Z, PIETTE JC, GODEAU P, BACH JF, K0UT-
ouzov 5: Presence of nucleosome-restricted antibodies in patients
with systemic lupus erythematosus. Arthritis Rheum 38:1485—1491,
1995
55. BURLINGAME RW, RUBIN RL, BALDERAS RS, THEOFILOPOULOS AN:
Genesis and evolution of anti-chromatin autoantibodies in murine
lupus implicates T-dependent immunization with self antigen. J Clin
Invest 91:1687—1696, 1993
56. AMOURA Z, CHABRE H, KovTouzov S, Loi-roi'i C, CABRESPINES A,
BACH iF, JACOB L: Nucleosome-restricted antibodies are detected
before anti-dsDNA and/or antihistone antibodies in serum of
MRL-Mp lpr/lpr and +/+ mice, and are present in kidney eluates of
lupus mice with proteinuria. Arthritis Rheum 37:1684—1688, 1994
57. MASSAM, DE BENEDETITI F, PIGNAi-rI P: Anti-double stranded
DNA, anti-histone and anti-nucleosome IgG reactivities in children
with systemic lupus erythematosus. Clin Exp Rheumatol 12:219—225,
1994
58. SMEENK RJT, HYLKEMA MN: Detection of antibodies to DNA: a
technical assessment. Mol Biol Rep 17:71—79, 1992
59. HYLKEMA MN: Autoimmunity against nucleosomes and lupus ne-
phritis. PhD thesis, University of Amsterdam, Amsterdam, 1995, p95
60. STEMMER C, RICHALET-SECORDEL P, VAN BRUGGEN MCJ, KRAMERS
C, BERDEN JHM, MULLER S: Dual reactivity of several monoclonal
anti-nucleosome autoantibodies for double stranded DNA and a
short segment of histone H3. J Biol Chem 271:21257—21261, 1996
61. KANWAR YS, Lw ZZ, KASHIHARA N, WALLNER El: Current status of
the structural and functional basis of glomerular filtration and
proteinuria. Semin Nephrol 11:390—413, 1991
62. VAN DEN BORN J, VAN DEN HEUVEL LPWJ, BAKKER MAH,
VEERKAMP JH, ASSMANN KIM, BERDEN JHM: A monoclonal anti-
body against GBM heparan sulfate induces an acute selective
proteinuria in rats. Kidney mt 41:115—123, 1992
63. SCHMIEDEKE TMJ, STOCKL FW, WEBER R, SUGISAKI Y, BATSFORD
SR, VOGT A: Histones have high affinity for the glomerular basement
membrane. J Exp Med 169:1879—1894, 1989
64. TERMAAT RM, ASSMAN MM, DLIKMAN HBPM, SMUENK RJT, BER-
DEN JHM: Anti-DNA antibodies can bind to the glomerulus via two
distinct mechanisms. Kidney mt 42:1363—1371, 1992
65. RAz E, BREZIS M, ROSENMANN E, EILAT D: Anti-DNA antibodies
bind directly to renal antigens and induce kidney dysfunction in the
isolated perfused rat kidney. J Immunol 142:3076—3082, 1989
66. DI VALERIO R, BERNSTEIN KA, VARGHESE E, LEFROWITH JB:
Murine lupus glomerulotropic monoclonal antibodies exhibit differ-
ing specificites but bind via a common mechanism. J Immunol
155:2258—2268, 1995
Nephrology Forum: Lupus nephritis 555
67. BERNSTEIN KA, Di VAI.ERI0 R, LEFKOWITI-I JB: Glomerular binding
activity in MRL lpr serum consists of antibodies that bind to a
DNA/histone/type IV collagen complex. J Immunol 154:2424—2433,
1995
68. BERNSTEIN KA, BOLSHOUN D, LEFKOWITH JB: Serum glomerular
binding activity is highly correlated with renal disease in MRL/lpr
mice. Clin Exp Immunol 93:418—423, 1993
69. BERNSTEIN KA, KAHL LE, BALOW JE, LEFKOWITH JB: Serologic
markers of lupus nephritis in patients: use of a tissue based ELISA
and evidence for immunopathogenic heterogeneity. Gun Exp Immu-
nol 98:60—65, 1994
70. vt BRUGGEN MCJ, WALGREEN B, RIJKE GPM, CoRsws MJAMM,
ASSMANN KJM, SMEENK RJT, VAN DEDEM GWK, KRAMERS C,
BERDEN JHM: Heparin and heparinoids prevent the binding of
immune complexes containing nucleosomal antigens to the GBM
and delay nephritis in MRL/lpr mice. Kidney mt 50:1555—1564, 1996
71. VAN DEN BORN J, VAN DEN HEUVEL LPWJ, BAKKER MAH,
VEERKAMP JH, ASSMANN KJM, BERDEN JHM: Monoclonal antibod-
ies against the core protein and the membrane glycosaminoglycan
side chain of glomerular basement membrane heparan sulfate pro-
teoglycan. Characterization and immunohistochemical application in
human tissues. J Histochem Cytochem 42:89—102, 1994
72. VAN DEN BORN J, VAN DEN HEUVEL LPWJ, BARKER MAH,
VEERKAMP JH, ASSMAN KJM, WEENING JJ, BERDEN JHM: Distribu-
tion of GBM heparan sulphate proteoglycan core protein and side
chains in human glomerular diseases. Kidney mt 43:454—463, 1993
73. VAN BRUGGEN MCJ, KRAMERS C, HYLKEMA MN, VAN DEN BORN J,
BAKKER MAH, ASSMANN KJM, SMEENK RJT, BERDEN JHM: De-
crease of heparan sulfate staining in the glomerular basement
membrane in murine lupus nephritis. Am J Pathol 146:753—763, 1995
74. VAN BRUGGEN MCJ, KRAMERS C, WALGREEN B, ELEMA JD, KAL-
LENBERG CGM, VAN DEN BORN J, ASSMANN KJM, SMEENK RJT,
MULLER 5, MONESTIER M, BERDEN JHM: Nucleosomes and histones
are present in glomerular deposits in human lupus nephritis. Nephrol
Dial Transplant 12:57—66, 1997
75. Siocici FW, MULLER S, BATSFORD 5, SCHMIEDEKE TMJ, WALDHERR
R, ANDRASSY K, SUGISAKI Y, NAKABAYASI-II K, NAGASAWA T,
RODRIGUEZ-ITURBE B, DONINI U, VOGT A: A role for histones and
ubiquitin in lupus nephritis? Clin Nephrol 41:10—17, 1994
76. VAN BRUGGEN MCJ, KRAMERS C, HYLKEMA MN, SMEENK RJT,
BERDEN JHM: Significance of anti-nuclear and anti-extracellular
matrix auto-antibodies for albuminuria in murine lupus nephritis. A
longitudinal study on plasma and glomerular eluates in MRL/lpr
mice. C/in Exp Immunol 105:132—139, 1996
77. LAMBERT PH, DixoN FJ, ZUBLER RH, AGNELLO V, CAMBIASO C,
CASALI P, CLARK J, COWDERY JS, MCDUFFIE MC, HAY FC,
MACLENNAN 1CM, MASSON P, MULLER-EBERHARD HJ, PENTINNEN
K, SMITH M, TAPPEINER G, THEOFILOPOULOS AN, VERROUST P: A
WHO collaborative study for the evaluation of eighteen methods of
detecting immune complexes in serum. J C/in Lab Immunol 1:1—15,
1978
78. AGNELLO V, KOFFLER D, EISENBERO JW, WINCHESTER RJ, KUNKEL
HG: Clq precipitins in the serum of patients with SLE and other
hypocomplementemic states: characterization of high and low mo-
lecular weight types. J Exp Med 134:228S—241S, 1971
79. ANTES U, HEINZ H-P, Loos M: Evidence for the presence of
autoantibodies to the collagen-like portion of Cl q in systemic lupus
erythematosus. Arthritis Rheum 31:457—464, 1988
80. SIEGERT CEH, DAHA MR, HALMA C, VAN DER VOORT EAM,
BREED VELD FC: lgG and IgA autoantibodies against Clq in systemic
and renal diseases. C/in Exp Rheumato/ 10:19—23, 1992
81. SIEGERT CEH, Da MR, SWAAK MG, VAN DER VOORT EAM,
BREEDVEI.D FC: The relationship between serum titers of autoanti-
bodies against CJq and age in the general population and in patients
with systemic lupus crythematosus. C/in Immunol Immunopathol
67:204—209, 1993
82. SIEGERT CEFI, DAHA MR, WESTEDT ML, VAN DER VOORT EAM,
BREEDVELD FC: lgG autoantibodies against Clq are correlated with
nephritis, hypocomplementaemia, and dsDNA antibodies in systemic
lupus erythematosus. J Rheumatn/ 18:230—234, 1991
83. SIEGERT CEH, DAs MR, TSENG C, COREMANS IEM, VAN Es LA,
BREEDVELD FC: Predictive value of IgG autoantibodies against Cl q
for nephritis in systemic lupus erythematosus. Ann Rheum Dis
52:851—856, 1993
84. SIEGERT CEH, DABA MR, VAN DER VOORT EAM, BREEDVELD FC:
IgO and IgA antibodies to the collagen-like region of Clq in
rheumatoid vasculitis. Arthritis Rheum 33:1646—1654, 1990
85. COREMANS IEM, SPRONK PE, BOOTSMA H, DAHA MR, VAN DER
VOORT EAM, KATER L, BREEDVELD FC, KALLENBERG CGM:
Changes in antibodies to Clq predict renal relapses in systemic lupus
erythematosus. Am J Kidney Dis 26:595—601, 1995
86. UWATOKO S, GAUTHIER J, MANNIK M: Autoantibodies to the colla-
gen-like region of the Clq deposit in glomeruli via Clq in immune
deposits. C/in Immuno/ Immunopatho/ 61:268—273, 1991
87. LIANG HM, SOCHER SA, LARSON MG, SCHUR PH: Reliability and
validity of six systems for the clinical assessment of disease activity in
systemic lupus erythematosus. Arthritis Rheum 32:1107—1118, 1989
88. HAY E, GORDON C, EMERY P: Assessment of lupus: where are we
now? Ann Rheum Dis 52:169—172, 1993
89. PONTICELLI C: Current treatment recommendations for lupus ne-
phritis. Drugs 40:19—30, 1990
90. APPEI, GV, VALERI A: The course and treatment of lupus nephritis.
Annu Rev Med 45:525—537, 1994
91. SI0AN RP, SCHWARTZ MM, KORBET SM, BOROK RZ, THE LuPus
NEPI-IRITI5 COLLABORATIVE STUDY GROUP: Long-term outcome in
systemic lupus eiythematosus membranous glomerulonephritis. JAm
Soc Nephro/ 7:299—305, 1996
92. BRUNS FJ, ADLER 5, FRALEY DS, SEGEL DP: Sustained remission of
membranous glomerulonephritis after cyclophosphamide and pred-
nisone. Ann mntem Med 114:725—730, 1991
93. REICHERT LJM, HUYSMANS FTHM, ASSMANN KiM, KOENE RAP,
WETZELS JFM: Preserving renal function in patients with membra-
nous nephropathy: daily oral chiorambucil compared with intermit-
tent monthly pulses of cyclophosphamide. Ann Intern Med 121:328—
333, 1994
94. FALK Ri, HOGAN SL, MULLER KE, JENETrE C, THE GLOMERULAR
DISEASE COLLABORATIVE NETWORK: Treatment of progressive mem-
branous glomerulopathy. A randomized trial comparing cyclophos-
phamide and corticosteroids with corticosteroids alone. Ann Intern
Med 116:438—445, 1992
95. RADI-IAKRISHNAN J, KUNIS CL, D'AGATI VD, APPEL GB: Cyclospor-
me treatment of lupus membranous nephropathy. C/in Nephro/
42:147—154, 1994
96. FEUTREN G, QUERIN 5, NOEL LH, CHATENOUD L, BEAURAIN G,
TRON F, LESAVRE P, BACH JF: Effects of cyclosporin in severe lupus
erythematosus. J Pediatr 111:1063—1068, 1987
97. NIELSON EG: Nephrology Forum: Pathogenesis and therapy of
interstitial nephritis. Kidney mt 35:1257—1270, 1989
98. BUYSEN JGM, HOUTHOFF Hi, KREDIET RT, ARISz L: Acute inter-
stitial nephritis: a clinical and morphological study in 27 patients.
Nephro/ Dia/ Transplant 5:94—99, 1990
99. CAMERON iS: What is the role of long-term cytotoxic agents in the
treatment of lupus nephritis? J Nephrol 6:172—176, 1993
100. FELSON DT, ANDERSON J: Evidence for the superiority of immuno-
suppressive drugs and prednisone over prednisone alone in lupus
nephritis. N Eng/ J Med 311:1528—1533, 1984
101. BALOW JE, AUSTIN HA III, MUENZ LR, JOYCE KM, ANTONOVYCH
IT, KLIPI'EL JH, STEINBERG AD, PLOTZ PH, DECKER JL: Effect of
treatment on the evolution of renal abnormalities in lupus nephritis.
NEng/JMed 311:491—495, 1984
102. AUSTIN HA III, MUENZ LR, JOYCE KM, ANTONOVYCH fl', BALOW
JE: Diffuse proliferative lupus nephritis: identification of specific
pathologic features affecting renal Outcome. Kidney mt 25:689—695,
1984
103. AUSTIN HA III, KLIPPEI, JH, BALOW JE, RICHE NGH, STEINBERG
AD, PLOTZ PH, DECKER JL: Therapy of lupus nephritis. Controlled
trial of prednisone and cytotoxic drugs. N Eng/ J Med 314:614—619,
1986
104. STEINBERG AD, STEINBERG SC: Longtcrm preservation of renal
function in patients with lupus ncphritis receiving treatment that
includes cyclophusphamide versus those treated with prednisone
only. Arthritis Rheum 34:945—950, 1991
105. ESDAILE JM, LEVINTON C, FEDERGREEN W, HAYSLETF JP, KASHGAR-
IAN M: The clinical and renal biopsy predictors of long term outcome
in lupus nephritis. Q J Med 72:779—833, 1989
556 Nephrology Fomm: Lupus nephritis
106. PONTICELLI C, ZUCCHELLI P, MORONI G, CAGNOLI L, BANFI 0,
PASQUALI S: Long-term prognosis of diffuse lupus nephritis. Gun
Nephrol 28:263—271, 1987
107. CAMERON JS, TURNER BR, OGG CS, WILLIAMS DG, LESSOF MH,
CHANTLER C, LEIBOWITZ S: Systemic lupus with nephritis: a long
term study. Q J Med 48:1—24, 1979
108. BOUMFAS DT, AUSTIN HA III, VAUGHAN EM, YARBORO CH,
KLIFPEL JH, BALOW JE: Risk for sustained amenorrhea in patients
with systemic lupus erythematosus receiving intermittent pulse cy-
clophosphamide therapy. Ann Intern Med 119:366—339, 1993
109. TROMPETER RS, EVANS PR, BARRATF TM: Gonadal function in boys
with steroid responsive nephrotic syndrome treated with cyclophos-
phamide for short periods. Lancet 1:1177—1179, 1981
110. DAVISON JM: Pregnancy in renal transplant recipients: clinical
perspectives. Contrib Nephrol 37:170—178, 1984
111. MCCUNE Wi, GOLBUS J, ZELDERS W, BOHLKE P, DUNNE R, Fox
DA: Clinical and immunologic effects of monthly administration of
intravenous cyclophosphamide in severe systemic lupus erythemato-
sus.NEngI J Med 318:1423—1431, 1988
112. HOFFMAN GS, KERR GS, LEAVITT RY, HALLAHAN CW, LEBOVICS
RS, TRAVIS WD, ROTTEM M, FAUCI AS: Wegener granulomatosis:
an analysis of 158 patients. Ann Intern Med 116:488—498, 1992
113. KINLEN UT: Incidence of cancer in rheumatoid arthritis and other
disorders after immunosuppressive treatment. Am J Med 78(suppl
1A):44—49, 1985
114. LIEBLING MR, MCLAUGHLIN K, BOONSUE S, KASDIN J, BARNETF EV:
Monthly pulses of methylprednisolone in SLE nephritis. J Rheumatol
9:543—548, 1982
115. BOUMPAS DT, AUSTIN HA III, VAUGHAN EM, KLIPPEL JH, STEIN-
BERG AD, YARBORO CH, BALOW JE: Controlled trial of pulse
methylprednisolone versus two regimens of pulse cyclophosphamide
in severe lupus nephritis. Lancet 340:741—745, 1992
116. GLAS-VOS JW, KREDIET RT, WEENING JJ, ARISZ L: Treatment of
proliferative lupus nephritis with methylprednisolone pulse therapy
and oral azathioprine. Neth J Med 46:4—14, 1995
117. VAN DEN WALL BAKE AWL, BERDEN JHM, DERKSEN RHWM,
Gs-VOS DE JW, HAGEN EC: Therapy of proliferative lupus
glomerulonephritis: a prospective trial in the Netherlands. Neth
J Med 45:280—284, 1994
118. JONES VJ, CUMMING RH, BACON PA, EVERS J, FRASER ID, BOTH-
AMLEY J, TRIBE CR, DAVIS P, HUGHES GRV: Evidence for a
therapeutic effect of plasmapheresis in patients with systemic lupus
erythematosus. QJ Med 192:555—576, 1979
119. LEAKER BR, BECKER GJ, DOWLING JP, KINCAID-SMITH PS: Rapid
improvement in severe lupus glomerular lesions following intensive
plasma exchange associated with immunosuppression. Gun Nephrol
25:236—244, 1986
120. WEI N, HUSTON DP, LAWLEY TJ, STEINBERG AD, KLIPPEL JH, HALL
RP, BALOW JE, DECKER JL: Randomized trial of plasma exchange in
mild systemic lupus erythematosus. Lancet 1:17—21, 1983
121. DERKSEN RHWM, HENE RJ, KALLENBERG CGM, VALENTIJN RM,
KATER L: Prospective multicentre trial on the short-term effects of
plasma exchange versus cytotoxic drugs in steroid-resistant lupus
nephritis. Neth J Med 33:168—177, 1988
122. LEWIS EJ, HUNSICKER LG, S11u-PING LAN MA, ROIIDE RD, LACHIN
JM: A controlled trial of plasmapheresis therapy in sevcre lupus
nephritis. N EnglJ Med 326:1373—1378, 1992
123. EULER HH, SCHROEDER JO, ZEUNER RA, TESKE EA: A randomized
trial of plasmapheresis and subsequent pulse cyclophosphamide in
severe lupus: design of the LPSG trial. mt J Artif Organs 14:639—646,
1991
124. MADORE F, LAZARUS JM, BRADY HR: Therapeutic plasma exchangc
in renal diseases (editorial review).JAm Soc Nephrol 7:367—386, 1996
125. BOOTSMA H, SPRONK PE, DERKSEN RHWM, DE BOER G, WOLTERS-
DICKE H, HERMANS J, LIMBURG PC, GMELIG-MEYLING FHJ, KATER
L, KALLENBERG CGM: Prevention of relapses in systemic lupus
erythematosus. Lancet 345:1595—1599, 1995
126. NOSSENT JC: End stage renal disease in patients with systemic lupus
erythematosus, in Lupus Nephritis, edited by Lewis EJ, Oxford,
Oxford University Press, in press
127. CHEIGH JS, STENZL KH: End-stage renal disease in systemic lupus
erythematosus. Am J Kidney Dis 21:2—8, 1993
128. NOSSENT JC, SWAAK AJG, BERDEN JHM: Systemic lupus erythema-
tosus: Analysis of disease activity in 55 patients with end stage renal
failure treated with hemodialysis or continous ambulatory peritoneal
dialysis. Am J Med 89:169—174, 1990
129. BOMBARDIER C, GLADMAN DD, UROWITZ MB, CARON D, CHANG
CH: Derivation of the SLEDAI. A disease activity index for lupus
patients. Committee on prognosis studies in SLE. Arthritis Rheum
35:630—640, 1992
130. COPLON N, SIEGELR, FRIES J: Hemodialysis in end stage renal lupus.
Trans Am Soc Artif Org 19:302—308, 1973
131. JARRET MP, SANTHANAN 5, DELGRECO F: The clinical course of
end-stage renal disease in systemic lupus erythematosus. Arch Intern
Med 143:1353—1356, 1983
132. COPLON N, DISKIN Ci, PETERSEN J, SWENSON RS: The long term
clinical course of systemic lupus erythematosus in end stage renal
disease. N Engl J Med 308:186—190, 1983
133. LEAKER B, FAIRLEY KF, DOWLING J, KINCAID-SMITH P: Lupus
nephritis: clinical and pathological correlation. QJMed 238:163—179,
1987
134. GLADMAN DD, GOLDSMITH CH, UROWITZ MB, BACON P, BOMBAR-
DIER C, ISENBERG D, KALUNIAN KG, LIANG MH, MADDISON P,
NIVED 0, RICHTER M, SNAITH M, SYMMONS D, ZOMA A: Sensitivity
to change of 3 systemic lupus erythematosus disease activity indices:
International validation. J Rheumatol 21:1468—1471, 1994
135. NOSSENT JC, SWAAK MG, BERDEN JHM: Systemic lupus erythema-
tosus after renal transplantation: patient and graft survival and
disease activity. Ann Intern Med 114:183—188, 1991
136. BUMGARDNER GL, MACER SM, ASCHER NL,PAYNEWD, DUNN DL,
FRYD DS, SUTHERLAND DER, SIMMONS RL, NAJARIAN iS: Long-
term outcome of renal transplantation in patients with systemic lupus
erythematosus. Transplant Proc 21:2031—2032, 1989
137. Goss JA, COLE BR, JENDRISAK MD, MCCULLOUGH CS, So SKS,
WINDUS DW, HANTO DW: Renal transplantation for systemic lupus
erythematosus and recurrent lupus nephritis. A single center expe-
rience and review of the literature. Transplantation 52:805—810, 1991
138. KRISI-INAN G, THACKER L, ANGSTAD JD, CAPELLI JP: Multicenter
analysis of renal allograft survival in lupus patients. Transplant Proc
23:1755—1756, 1991
139. NYBERG G, BLOHME I, PERSSON H, OLAUSSON M, SVALANDER C:
Recurrence of SLE in transplanted kidneys: a follow-up transplant
biopsy study. Nephrol Dial Transplant 7:1116—1123, 1992
140. AUSTIN HA III, MUENZ LR, JOYCE KM, ANTONOVYCH TA, KULLICK
ME, KLIPPEL JH, DECKER JL, BALOW JE: Prognostic factors in lupus
nephritis. Contribution of renal histologic data. Am J Med 75:382—
391, 1983
141. LEVEY AS, LAN SMPH, CORWIN HL, KASINATH BS, LACHIN JSD,
NEILSON EG, HUNSICKER LG, LEWIS EJ: Progression and remission
of renal disease in the lupus nephritis collaborative study. Results of
treatment with prednisone and short-term oral cyclophosphamide.
Ann Intern Med 116:114—123, 1992
142. NOSSENT JC, HENZEN-LOGMANS SC, VROOM TM, BERDEN JHM,
SWAAK TJG: Contribution of renal biopsy data in predicting Outcome
in lupus nephritis. Arthritis Rheum 33:970—977, 1990
143. AUSTIN HA III, BOUMPAS DT, VAUGHAN EM, BALOW JE: High risk
features of tupus nephritis: importance of race and clinical and
histological factors in 166 patients. Nephrol Dial Transplant 10:1620—
1628, 1995
144. GOULET JR, MACKENZIE T, LEVINTON C, HAYSLETF JP, CIAMPI A,
ESDAII.E JM: The long-term prognosis of lupus nephritis: the impact
of disease activity. J Rheumatol 20:59—65, 1993
145. APPEL GB, CohEN DJ, PIRANI CL, MEI.TZER JI, ESTES D: Longterm
follow up of patients with lupus nephritis. Am J Med 83:877—885,
1987
146. AUSTIN HA Ill, BOUMPAS DT, VAUGHAN EM, BALOW JE: Predicting
renal outcome in severe lupus nephritis: contributions of clinical and
histological data. Kidney Int 45:544—550, 1994
147. VALERI A, RADHAKRISHNAN J, ESTES D, D'AGATI V, KOPELMAN R,
PERNIS A, FLIS R, PIRANI C, APPEL GB: Intravenous pulse cyclo-
phosphamide treatment of severe lupus nephritis: a prospective
five-year study. Gun Nephrol 42:71—78, 1994
148. DONADIO JV, HOLLEY KE, FERGUSON RH, ILSTRUP DM: Treatment
of diffuse proliferative lupus nephritis with prednisone and combined
prednisone and cyclophosphamide. N EngI J Med 299:1151—1155,
1978
Nephrology Fomm: Lupus nephritis 557
149. PETRI M, PEREZ-GUTHANN S, LONGENECKER J, HOCHBERG M:
Morbidity of systemic lupus erythematosus: role of race and socio-
economic status. Am J Med 9 1:345—353, 1991
150. BAKIR AA, LEVY PS, DUNEA G: The prognosis of lupus nephritis in
African-Americans: a retrospective analysis. Am J Kidney Dis 24:
159—171, 1994
151. KRAMERS C, STEMMER C, MONESTIER M, VAN BRUGGEN MCJ, RIJKE
GPM, HYLKEMA MN, SMEENK RJT, MULLER S, BERDEN JHM:
Specificity of monoclonal anti-nucleosome auto-antibodies derived
from lupus mice. JAutoimmunily 9:723—729, 1996
152. LOSMAN MJ, FASY TM, NovicK KE, MONESTIER M: Monoclonal
autoantihodies to subnucleosomes from a MRL/Mp(-)/+/+ mouse.
Oligoclonality of the antibody response and recognition of a deter-
minant composed of histones H2A, H2B, and DNA. J Immunol
148:1561—1569, 1992
153. LOSMAN JA, FASY TM, NOVICK KE, MASSA M, MONESTIER M:
Nucleosome-specific antibody from an autoimmune MRL/Mp-lpr/!pr
mouse. Arthritis Rheum 36:552—560, 1993
154. EHRENsrEIN M, LONGHURST C, IsENBERG DA: Production and
analysis of IgG monoclonal anti-DNA antibodies from systemic
lupus erythematosus (SLE) patients. Gun Exp Immunol 92:39—45,
1993
155. KALIYAPERUMAI. A, MOHAN C, WE W, DATTA SK: Nucleosomal
peptide epitopes for nephritis-inducing T helper cells of murine
lupus. J Exp Med 183:2459—2469, 1996
156. PANKEWYCZ OG, MIGLI0RINI P, MADAIO MP: Polyreactive autoan-
tihodies are nephritogenic in murine lupus nephritis. J Immunol
139:3287—3294, 1987
157. SABUAGA J, PANKEWYCZ OG, LUFEr V, SCHWARTZ RS, MADAIO MP:
Cross-reactivity distinguishes serum and ncphritogenic anti-DNA
antibodies in human lupus from their natural counterparts in normal
serum.] Autoimmun 3:215—235, 1990
158. VLAHAKOS D, FOSTER MH, UCCI AA, BARRETT KJ, DAl-rA SK,
MADAIO MP: Murine monoclonal anti-DNA antibodies penetrate
cells, hind to nuclei, and induce glomerular proliferation and pro-
teinuria in vivo. JAm Soc Nephrol 2:1345—1354, 1992
159. KRAMILRS C, VAN BRUGGEN MCJ, RuI GPM, DIJKMAN HBPM,
HYLKEMA MN, CROES Hi, FRANSSEN JAM, ASSMANN K, TAX WJM,
SMEENK RJT, BURDEN JHM: In vivo ANA is a fixation artifact.
Nucleosome complexed anti-nucleosome antibodies hind to the cell
surface and are internalized. JAm Soc 1'/ephrol 7:946—954, 1996
160. KouTouzoV S, CABRESPINES A, AMOURA Z, CHABRE H, LorroN C,
BACH JF: Binding of nucleosomes to a cell surface receptor: redis-
tribution and endocytosis in the presence of lupus antibodies. Eur
J Immunol 26:472—486, 1996
161. TERMAAT RM, BRINKMAN K, NOSSENT JC, SWAAK AJG, SMEENK
RJT, BERDEN JHM: Anti-heparan sulphate reactivity in sera from
patients with systemic lupus erythematosus with renal or non-renal
manifestations. Clin Exp Immunol 82:268—274, 1990
162. KRAMERS C, TERMAAT RM, TER BORG EJ, VAN BRUGGEN MCJ,
KALI.ENBERG CGM, BERDEN JHM: Higher anti-heparan sulphate
reactivity during SLE exacerbations with renal manifestations. A
long term prospective analysis. Clin Exp Immunol 93:34—38, 1993
163. OHNISI-II K, EBLING FM, MITCHELL B, SING RR, HAHN BH, TSAO BP:
Comparison of pathogenic and non-pathogenic murine antibodies to
DNA: antigen binding and structural characteristics. mt Immunol
6:817—830, 1994
164. Fox DA, MCCUNE WJ: Immunosuppressive drug therapy of systemic
lupus erythematosus. Rheum Dis Clin North Am 20:265—299, 1994
165. RADHAKRISHNAN J, VALERI A, KUNIS CL, APPEL GB: Use of
cyclosporin in lupus nephritis. Contrib Nephrol 114:59—72, 1995
166. BURDEN JHM, FAABER P, ASSMANN KJM, RIJKE GPM: Effects of
cyclosporin A on autoimmune disease in MRL/I and BxSB mice.
Scand J Immunol 24:405—412, 1986
167. GANSEVOORT RT, SLUITER WJ, HEMMELDER MH, DE ZEEUW D, DE
JONG PE: Anti-proteinuric effect of blood-pressure-lowering agents:
a meta-analysis of comparative trials. Nephrol Dial Transplant 10:
1963—1974, 1995
168. EDDY AA: Experimental insights into the tubulointerstitial disease
accompanying primary glomerular lesions. JAm Soc Nephrol 5:1273—
1287, 1994
169. BOHLE A, MUELLER GA, WEHRMANN M, MACKENSEN-HAEN 5, X.o
JC: Pathogenesis of chronic renal failure in the primary glomeru-
lopathies, renal vasculopathies and chronic interstitial nephritides.
Kidney list 49(suppl 54):S2—S9, 1996
170. NAKAYAMA K, NEGISHI I, KUIDA K, SI-IINKAI Y, LOUIE MC, FIELDS
LE, LUCAS PJ, STEWART V, ALT FW, Loll DY: Disappearance of the
lymphoid system in Bcl-2 homozygous mutant chimeric mice. Science
261:1584—1588, 1993
171. VEIS DJ, SORENSON CM, SllurrtiR JR, KORSMEYER SJ: Bcl-2-
deficient mice demonstrate fulminant lymphoid apoptosis, polycystic
kidneys, and hypopigmented hair. Cell 75:229—240, 1993
172. VAN EDEN W: Heat shock proteins as inimunogenetic bacterial
antigens with the potential to induce and regulate auto-immune
arthritis. Immunology 121:5—12, 1996
173. PUSEY CD, RUES AJ, EVANS DJ, PETERS K, LOCKWOOD CM:
Plasma-exchange in focal necrotizing glomerulonephritis without
anti-GBM antibodies. Kidney mt 40:757—763, 1991
174. FRAMPTON G, HICKS JA, CAMERON JS: Significance of anti-phospho-
lipid antibodies in patients with lupus nephritis. Kidney mt 39: 1225—
1231, 1991
175. PIErrE JC, CAC0UB P, WECHSIER, B: Renal manifestations of the
antiphospholipid syndrome. Semin Arthritis Rheum 23:357—366, 1994
176. HUGHSON MD, NADASDY T, MCCARTHY GA, SHOLER C, MIN KW,
SILVA F: Renal thrombotic microangiopathy in patients with systemic
lupus erythematosus and the antiphospholipid syndrome. Am J
Kidney Dis 20:150—158, 1992
177. ASHERON RA: The catastrophic anti-phospholipid syndrome (edito-
rial). J Rheumatol 19:508—5 12, 1992
178. CHEIGH JS, KIM H, STENZEL KH, TAPIA L, SUI.LIVAN JF, STU[3EN-
I3ORD RR, RIGGIO RR, RUBIN AL: Systemic lupus erythematosus in
patients with end-stage renal disease: Long-term follow-up on the
prognosis of patients and the evolution of lupus activity. Am J Kidney
Dis 16:189—195, 1990
179. LUQMANI RA, PALMER RG, BACON PA: Azathioprine, cyclophospha-
mide and chlorambucil. Baillieres Clin Rheumatol 4:595—619, 1990
180. ALlISON AC, EUGUI E: Immunosuppressive and other effects of
mycophenolic acid and an ester prodrug, mycophenolate mofetil.
Immunol Rev 136:5—28, 1993
181. THOMSON AW, STARZL T: New immunosuppressive drugs: mecha-
nistic insights and potential therapeutic advances. Immunol Rev
136:71—98, 1993
182. COMA D, ZOJA C, FACCHINITJ D, M0RIGI M, REMUZZI G: Mycophe-
nolate mofetil prolongs life survival in murine lupus autoimmune
disease (abstract). JAm Soc Nephrol 6:825, 1995
183. WARNER LM, ADAMS LM, SEHGAL SN: Rapamycin prolongs survival
and arrests pathophysiological changes in murine systemic lupus
erythematosus (abstract). Arthritis Rheum 37:289—297, 1994
184. TAKABAYASHI K, KOIKE T, KURASAWA K, MATSUMURA R, SATO T,
TOMIOKA H, ITO I, YOSISIKI T, YOSHIDA 5: Effect of FK506, a novel
immunosuppressive drug on murine systemic lupus erythematosus
(abstract). Clin Immunol Immunopathol 51:110—117, 1989
185. KIMATA H, Y05HIDA A, I5HIOKA C, MIKAWA H: Erythropoietin
enhances immunoglobin production and proliferation by human
plasma cells in a serum-free medium. Clin mmmunol Immunopathol
59:495—501, 1991
186. SENNSAEL JJ, VAN DER NIEPEN P, VERBEELEN DL: Treatment with
recombinant human erythropoietin increases antibody titers after
hepatitis B vaccination in dialysis patients. Kidney list 40:121—128,
1991
187. HEBERT LA, BIRMINGHAM DJ, SHEN XP, BRANDT JT, SEDMAK DD,
DILLON DJ: Effect of recombinant erythropoietin therapy on auto-
immunity in systemic lupus erythematosus. Am J Kidney Dis 24:25—
32, 1994
188. PARKE AL: Pregnancy and systemic lupus erythematosus, in Systemic
Lupus Eiythematosus, edited by LAHITA RG, New York, Churchill
Livingstone, 1992, p 543
189. SWAAK AJG, AARDEN LA, STATIUS VAN EPs LW, FELTKAMP TEW:
Anti-dsDNA and complement profiles as prognostic guides in SLE.
Arthritis Rheum 22:226—235, 1979
190. SWAAK AJG, GROENWOLD 3, AARDEN LA, FELTKAMP TEW: Detec-
tion of anti-dsDNA as diagnostic tool. Ann Rheum Dis 40:45—49,
1981
191. SWAAK AJG, GROENWOLD J, AARDEN LA, STATIUS VAN EP5 LW,
FELTKAMP TEW: Prognostic value of anti-dsDNA in SLE. Ann
Rheum Dis 41:388—395, 1982
558 Nephrology Forum: Lupus nephritis
192. SwK MG, GROENWOLD J, BRONSVELD W: Predictive value of
complement profiles and anti-dsDNA in systemic lupus eiythemato-
sus. Ann Rheum Dis 45:359—366, 1986
193. MILLER MH, UR0wITz MB, GLADMAN DD, KILLINGER DW: Sys-
temic lupus erythematosus in males. Medicine 62:327—334, 1983
194. KAUFMANN LD, GOMEZ-REINO JJ, HEINICKE MH, GoRevIc PD:
Male lupus: retrospective analysis of the clinical and laboratory
features of 52 patients, with a review of the literature. Am J Kidney
Dis 18:189—197, 1989
195. GRUNKE M, LORENZ H-M, HIERONYMUS T, HERRMANN M, GEILER
T, HEYDER P, MANGER B, KALDEN JR: Altered in vitro apoptosis and
expression of apoptosis-related molecules in SLE lymphocytes are
phenomena not specific for SLE (abstract). Arthritis Rheum 39(suppl
9):S142, 1996
196. HERRMANN M, ZOLLER OM, HAGENHOFER M, VOLL R, KALDEN JR:
Macrophages from SLE patients have a reduced capacity to engulf
apoptotic cells (abstract). Arthritis Rheum 39(suppl 9):S143, 1996
197. SAVILL J: The innate immune system: recognition of apoptotic cells,
inApoptosis and the Immune Response, edited by GREGORY CD, New
York, Wiley-Liss, 1995, p 341
198. F0URNIE GJ: Detection of nucleosome-IgG immune complexes in
ascites from mice transplanted with anti-DNA antibody-screening
hybridomas and in plasmas from MRL-lpr/lpr mice. Clin Exp Immu-
no! 104:236—240, 1996
199. JORDAN SC: Intravenous gamma-globulin therapy in systemic lupus
erythematosus and immune complex disease. Clin Immunol Immu-
nopathol 53:S164—S169, 1989
200. SANY J: Intravenous immunoglobulin therapy for rheumatic diseases.
Curr Opin Rheumatol 6:305—310, 1994
201. RIVERA M, MARCEN R, PASCUAL J, NAYA MT, OR0FIN0 L, ORTUNO
J: Kidney transplantation in systemic lupus erythematosus nephritis:
a one-center experience. Nephron 56:148—151, 1990
202. GIMOVSKY ML, BENNER P, MONTORO M, PLAI-I- DL, BERNE T, PAUL
RH: Successful pregnancy in a patient with systemic lupus erythem-
atosus, renal transplantation and chronic renal failure. A case report.
J Reprod Med 28:677—680, 1983
203. GRIEM P, PANTHEL K, KALBACHER H, GLEICFIMANN E: Alteration of
a model antigen by Au(III) leads to T cell sensitization to cryptic
peptides. Eur J Immunol 26:279—287, 1996
204. ATEN J, PRIGENT P, PONCET P, BLANPIED C, CLAESSEN N, DRUET PH,
HIRSCH F: Mercuric chloride-induced programmed cell death of a
murine T cell hybridoma. Cell Immunol 161:98—106, 1995
205. BOUMPAS DT, AUSTIN HA III, FESSLER BJ, BALOW JE, KLIPPEL JH,
LOCKSHIN MD: Systemic lupus erythematosus: emerging concepts.
Part 1. Renal, neuropsychiatric, cardiovascular, pulmonary and he-
matologic disease. Ann Intern Med 122:940—950, 1995
206. CIRUELO E, DE LA CRUZ J, LOPEZ I, GOMEZ-REINO JJ: Cumulative
rate of relapse of lupus nephritis after successful treatment with
cyclophosphamide. Arthritis Rheum 39:2028—2034, 1996
207. M0R0NI G, BANFI G, PONTICELLI C: Clinical status of patients after
10 years of lupus nephritis. Q J Med 84:681—689, 1992
208. MEJIA G, ZIMMERMAN SW, GLASS NR, MILLER DT, SOLLINGER HW,
BELZER FO: Renal transplantation in patients with systemic lupus
erythematosus. Arch Intern Med 143:2089—2092, 1983
209. BUMGARDNER GL, MAUER SM, PAYNE WD, DUNN DL, SUTHER-
LAND DER, FRYD DS, ASCHER NL, SIMMONS RL, NAJARIAN JS:
Single center 1—15 years results of renal transplantation in patients
with systemic lupus erythematosus. Transplantation 46:703—709, 1988
